\r\n\tTSC involves mutations in chromosomes 9 and 16 encoding for the proteins hamartin and tuberin, respectively. Mutations in these genes cause upregulation of the mTOR pathway and inhibitors of this pathway, such as rapamycin and everolimus, have been shown to be effective in controlling the growth of unresectable tumors. Due to involvement of multiple organ systems, a multidisciplinary treatment plan is necessary and genetic counseling is often part of the management of TSC. Treatment options are quite variable and depended upon symptoms and organ involvement.
\r\n\r\n\tThe aim of this book is to provide the reader with an overview of the tuberous sclerosis complex including its genetic causes, clinical manifestations, and management of its most serious signs and symptoms.
",isbn:null,printIsbn:"979-953-307-X-X",pdfIsbn:null,doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"763892736c7dfc107dc82453265142ad",bookSignature:"Dr. Scott Turner",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10438.jpg",keywords:"Hypomelanotic Macules, Shagreen Patches, Cardiac Rhabdomyoma, Pulmonary Lymphangioleiomyomatosis, Renal Angiomyolipoma, Genetic Testing, Hamartin, Tuberin, Tubers, Subependymal Nodule, Subependymal Giant Cell Astrocytoma, Rapamycin",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"July 2nd 2020",dateEndSecondStepPublish:"July 23rd 2020",dateEndThirdStepPublish:"September 21st 2020",dateEndFourthStepPublish:"December 10th 2020",dateEndFifthStepPublish:"February 8th 2021",remainingDaysToSecondStep:"7 months",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:null,kuFlag:!1,biosketch:"Dr. Turner received his medical degree from the Medical College of Wisconsin. He completed a neurology residency at the State University of New York in Stony Brook and a neuro-oncology fellowship at Duke University. He specializes in the treatment of primary and metastatic tumors of the brain and spine. Dr. Turner's undergraduate and master's degree in molecular biology and biochemistry is critical in understanding the complex mechanisms involved with tumor biology.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"181611",title:"Dr.",name:"Scott",middleName:null,surname:"Turner",slug:"scott-turner",fullName:"Scott Turner",profilePictureURL:"https://mts.intechopen.com/storage/users/181611/images/system/181611.png",biography:"Dr. Scott Turner is a clinical Neuro-oncologist and Associate Professor of Neurology at the University of California, Irvine. He attended graduate school at Cornell University and received his medical degree from the Medical College of Wisconsin in 2003. He completed a Neurology residency at SUNY Stony Brook followed by a Neuro-oncology fellowship at Duke University in 2010. He has served as an Assistant Professor of Neurology at both Temple University and the University of Missouri - Kansas City School of Medicine. He has participated in many clinical trials in the field and is interested in the mechanism of glioma cell invasion.",institutionString:"University of California, Irvine",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"University of California, Irvine",institutionURL:null,country:{name:"United States of America"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"297737",firstName:"Mateo",lastName:"Pulko",middleName:null,title:"Mr.",imageUrl:"https://mts.intechopen.com/storage/users/297737/images/8492_n.png",email:"mateo.p@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"74428",title:"Wine Stabilisation: An Overview of Defects and Treatments",doi:"10.5772/intechopen.95245",slug:"wine-stabilisation-an-overview-of-defects-and-treatments",body:'All around the world in wine production many sensory defects, physicochemical instabilities, and a few toxic compounds can appear, which usually results in a decrease of the wine quality and/or safety, being responsible for economic losses for the wine industry. Nowadays, the origin of most wine defects and processing conditions that favour their formation are well identified. At the same time, many viticultural and technological solutions are available to completely or partially avoid their formation, and various additives and fining agents are allowed to be used to avoid their formation or remove the compounds, or their precursors, responsible for the instability [1]. Frequently, the question is not how to remove the defect or their precursors, but how to remove it without changing the wine sensory profile.
The most troublesome defects for wine producers are those occurring after wine bottling, as the intervention at this stage is rather limited and therefore preventive actions are the most efficient and sometimes the only strategy. After wine bottling the main external factor that can influence wine stability and the kinetics of the chemical reactions and interactions of the wine constituents is the temperature that can significantly affect for example the solubility of tartrate salts, induce colour changes in red and white wines, and the formation of protein haze. Also, the redox potential, mainly determined by the levels of dissolved oxygen in the wine can significantly influence the wine shelf life. Before bottling, depending on the wine defect to be treated two main stabilisation strategies are currently used: subtractive and non-subtractive. For the first approach fining agents are used that can interact with the compound(s) responsible for the wine defect or their precursors removing them from the wine. In the second type of strategy, an additive is added to the wine that interacts with the compound(s) responsible for the wine defect affecting their ability to form crystals as in the case of carboxymethylcellulose in the tartaric instability [2] or decrease the vapour pressure of the compound(s) responsible for an undesirable odour for example like chitosan in the case of the ethylphenols responsible for the ‘Brett character’ [3].
In the next sections (2, 3, 4, and 5) the main wine defects and their stabilisation treatments currently allowed and used will be overviewed as well as the stabilisation treatments currently under research. For a matter of simplicity and systematisation, the wines defect that can occur in wine production are divided into four main groups according to their impact on the wine sensory quality and safety: (1) visual sensory defects; (2) off-odours and taints; (3) taste and tactile defects (4) safety-related defects. The wine visual defects are concerned with changes in wine limpidity and undesirable colour changes that can occur during wine production and especially after wine bottling. These defects can be due to the formation of precipitates related to solubility issues, the formation of precipitates related to the colloidal instability of some wines components, the reaction between wine components, or due to the oxidation of wine phenolic compounds.
Wine aroma significantly determines consumer acceptability [4], being extremely complex as it is the result of the cumulative effect of a diverse group of volatile compounds present at levels ranging from fractions of ng/L up to mg/L. These compounds can interact with the olfactory epithelium to generate a sensory perception [5, 6]. The levels of these volatiles are dependent on both viticultural [7] and oenological practices [8, 9]. Although several hundreds of these volatile compounds can be present in wines [10], only a few are present at levels above the perception threshold and thus being responsible for characteristic odours [11]. During wine production, several off-odours and taints can cause severe quality problems. Off-odours are considered to be the occurrence of any atypical odours resulting from compounds formed by the deterioration of the wine, including chemical reactions and microbial spoilage; whereas, taints result from external contamination of the wine as a result of exposure of grapes to contaminating environments or migration of compounds form packaging materials contaminated by either synthetic chemicals or chemicals produced or transformed by microbial action [12]. Sometimes, compounds that impart a positive aroma character in one instance may cause an off-odour when present in the wrong context or at high levels. Besides, faults in one wine may not be undesirable in another: for example, the complex oxidised bouquets of Sherries, the fusel odours of Port wine, and the baked character of Madeira wine. Some faults, such as a barnyard odour, generated by ethylphenols, may be considered pleasingly ‘rustic,’ or part of the terroir character of certain wines. The evident presence of ethyl acetate in the aroma of wine is also usually considered a fault. However, in expensive Sauternes, it appears to be acceptable (or ignored). Nevertheless, there is general agreement among most wine professionals as to what constitutes an aromatic fault in table wines. These wine defects, their origin, and their sensory impact are discussed in Section 2. Balancing the oral sensations of wine is one of the most demanding tasks for a winemaker since a distinguishing feature of superior wines is the harmony achieved among these seemingly simple sensations. Indeed, imbalances created by excessive acidity, astringency, or bitterness, among others, are often the first deficiencies noted by a panellist [13]. Since it is very important to understand the factors that affect the sensory properties responsible for wine taste and tactile imbalance, to allow the wine industry to be able to control these sensory characteristics of the final product from the first production stages. The main wine taste and tactile defects are astringency, bitterness, and acidity imbalance. Wine astringency is caused by excess proanthocyanidins in young red wine, it is considered a tactile sensation [14], responsible for the ‘drying’, ‘roughing’ and ‘puckering’. The ageing process reduces astringency due to oxidation and will be less evident in aged wines. Bitterness is a taste perception related to phenolic compounds with low molecular weights such as flavonol aglycones, especially myricetin or quercetin [15] as well as to monomeric or small phenolic flavanols [16]. Bitterness, astringency, and acidity could change depending on the oenological practice. In Section 4 the sensory impact of excessive astringency, bitterness and acidity will be highlighted, as well as the stabilisation/correction strategies.
In Section 5, the formation of the main potential toxic compounds that affect wine safety is overviewed. These compounds are present in wines due to the activity of bacteria and moulds in the wine production and due to the bad hygienic sanity of the grapes used for winemaking, respectively.
The two most important visual sensory defects that affect wine quality occur during the storage of bottled wine. These are the tartrate instabilities and protein instability. Other instabilities that can occur include red wine colour colloidal instability, pinking of certain white wines produced from white grape varieties, browning of white and rose wines, and oxidation of all wines as well as metallic instabilities such as iron and copper instability.
The crystallisation of potassium hydrogen tartrate or calcium tartrate salts may occur in wines where their concentration product exceeds their solubility product [17, 18]. The formation of these crystals results in the formation of deposits at the bottom vat and sometimes in the bottled wine. Prevention of tartaric precipitation in bottled wine is essential as consumers associate its occurrence with poor production conditions or an exogen wine material. Methods to prevent tartaric crystals precipitation include metatartaric acid, cold stabilisation, and electrodialysis [19]. The addition of mannoproteins obtained from the hydrolysis of the yeast cell wall was authorised by the European Community since 2005 [19]. Mannoproteins inhibit the crystallisation of tartrate salts by lowering the crystallisation temperature [20] preventing the occurrence of precipitates in wine [21]. Arabic gum can also have some effectiveness to prevent tartaric instability, as they are protective colloids [22], and more recently sodium carboxymethylcellulose for white wine (since 2009) and potassium polyaspartate (since 2015) were authorised [19].
Precipitation of soluble proteins in bottled wines can also occur and this results in the formation of an amorphous haze or deposit. This defect occurs frequently in white wines or wines with low polyphenol content. It is rare in wines with relatively high levels of flavonoid phenols, particularly tannins, which complex and precipitates proteins during wine production. The most important proteins that have been related to wine protein instability are pathogenesis-related proteins of Vitis vinifera that include the chitinases and thaumatin-like proteins as described by Tian et al. [23]. The formation of wine protein haze is a multifactorial process with several factors known to influence the process, such as storage or wine ageing temperature, pH, ionic strength, wine protein composition, organic acids, ethanol, phenolic compounds, metals, and sulphate content; however, other important factors remain unidentified, such as the non-proteinaceous component(s) usually named X factor [24]. These proteins can be slowly denatured and aggregate throughout wine storage, forming a light-dispersing haze; therefore, this phenomenon needs to be prevented by removing them from the wine, usually by fining, before wine bottling [25]. Bentonite fining is the most used process to avoid protein instability in white wine, with the dose used being preferentially determined previously by stability tests [25]. However, bentonite fining can have a detrimental effect on wine quality, for example, by the removal of colour and aroma compounds [26]. Therefore, alternative techniques to bentonite fining have been studied, such as ultrafiltration, the addition of proteolytic enzymes, flash pasteurisation, other adsorbents, zirconium oxide, natural zeolites, chitin and chitosan, carrageenan and the use of some mannoproteins [25].
Colour instability of some red wines can cause product depreciation. In the last years, excessive precipitation of colouring matter has been observed at the bottom of the storage tanks and even in bottled wines [27]. This precipitation occurs along with the natural evolution of red wine during the storage period and results in a considerable modification of its colour and limpidity that is undesirable in terms of visual perception and loss in taste and flavour [22]. This precipitate may happen after a few months of ageing. It may be sometimes gelatinous and strongly red coloured. If the red wine is aged and bottled, the precipitate may occur later in the form of a thin leaf, lining the inner side of the bottles [28]. A method commonly used to reduce wine turbidity and stabilise the colouring matter is fining by the addition of proteins (albumin, casein, or gelatine) that promotes flocculation or precipitation before bottling [29]. However, in some cases, the precipitate formation can still be observed in the later stages of the ageing process. The addition of arabic gum could prevents wine colour instability [22].
Two metal-dependent instabilities can also result in the formation of wine turbidity or deposits. Excess levels of iron (5–20 mg/L) in wine (white or red) can lead to the formation of precipitates with phosphates and tannins resulting in instabilities (iron (III) phosphate [white casse] or tannate [blue casse]). Application of arabic gum or casein/potassium caseinate or citric acid (< 1 g/L) is used to prevent this instability [30]. Copper instability occurs only in white wines, initially as a white haze, and later as a reddish-brown amorphous precipitate, develop upon storage of bottled wine with excess copper (> 0.5 mg/L), under strong reducing conditions and in the presence of SO2. This metal instability is caused by a reaction of metal traces, mainly copper from machinery, pesticide residues, or treatment with copper sulphate for the treatment of reductive off-flavours [31]. The OIV recommends a maximum copper content of 1.0 mg/L in wines [32]. The application of arabic gum is used to prevent this instability [30]. The protective colloids prevent metal precipitation but do not eliminate the copper. Exchange resins such as polyvinylimidazole-polyvinylpyrrolidone copolymers with selective binding of metals such as copper or iron have been developed [33]. The occurrence of iron and copper-related precipitations are much less usual due to the reduction of the level of these metals in the wines all-around the world by the use of stainless steel vats and wood barrels in the wine production, vat taps, and plastic polymers in the winery hoses, press machines and filling machines.
One of the most frequent oenological problems in winemaking is premature wine oxidation, especially the oxidative spoilage of young white wines causing wine browning [34]. During winemaking and bottle-ageing wine, components react with oxygen [35]. Moderate oxidation of red wines phenolic compounds can contribute positively to the red wine colour stabilisation and decrease wine astringency, nevertheless, excessive oxidation can have negative effects on wine quality [36]. Wine oxidation generally results in wine colour changes, an important sensory attribute that is the first to be appreciated by consumers. Today the market wants white wines with a citrine colour, almost colourless, except for those white wines fermented in oak barrels or wines with some ageing time. In rosé wines, many colours can be found on the market, since the ‘Provence style’, with a slight salmon colour, until rosé wines with the colour of open coloured red wines like ‘Palhete’, wines produced with white and red grapes and with some maceration. In the red wines, many styles and colours can be found, from the faint colour of Pinot Noir wines to the wines produced with Alicante Bouschet or Vinhão grape varieties that yield wines with intense red colours. The fast colour change in a white or rosé bottled wine is normally the result of an oxidative problem.
The deleterious browning reaction in must and wine occurs due to the oxidation of phenolic compounds and can start as soon the grapes are crushed due to the polyphenol oxidase activity. Polyphenol oxidase with tyrosinase and catecholase activity are natural enzymes present in grape berry. They can catalyse the oxidation of monophenols to o-diphenols and further oxidation to orthoquinone. In wine hydroxycinnamates and flavanols, such as caffeoyltartaric acids and catechin, respectively [37] are oxidised to the corresponding quinones. Further reaction of the quinones can result in the formation of a brown colour, especially that of catechin than can yield by dimerisation the yellow dehydrodicatechin B [38] Another problem can arise when grapes are affected with Botrytis cinerea [39] and the resulting must become contaminated with laccase enzyme. Laccase catalyses the one-electron oxidation of a broad range of compounds including substituted phenolics to the corresponding radicals [40]. Wine phenolic acids, catechins, anthocyanins, tannins, and stilbenes are converted into the corresponding quinones, which often react further to dark coloured polymers [41]. The latter are generally insoluble in water and precipitate out from must and wine. Grape polyphenol oxidase is sensitive to low concentrations of SO2 being inactivated, but laccase is more resistant to SO2, and it may be present in the final wine [22], while polyphenol oxidase rarely survives the fermentation process [42]. After fermentation, with the enzyme removed or inactivated, oxidation reactions in white wine are based on non-enzymatic pathways, where Fe (II) is oxidised to Fe (III), producing hydrogen peroxide, and the following reaction where Fe (III) coordinates with catechols and oxidises them to semiquinones [43]. Then the semiquinones disproportionate to form reactive electrophilic quinones and these reactive compounds have a key impact on wine chemistry, by degrading several colour and flavour substances [35]. Reactions of oxidation products with flavonoids are well known, and some of the products are pigmented. When tartaric acid is oxidised to glyoxal, the resulting bridged product continues to react, creating a xanthylium product that absorbs in the visible region, and may contribute to the yellow hue of oxidised wines [44].
To avoid the fast colour evolution, the winemakers use SO2 that due to their antioxidant and antioxidasic properties protect wine colour [45]. Unlike grape oxidases, which are inhibited by sulphites even at low levels, fungal laccases tend to be more resistant. The most effective treatment to eliminate the laccase activity in the must is heat treatment (2 min, 75°C). Ascorbic acid reduces and recycles quinones back to their original catechol forms, being generally used in pre-bottling. The presence of other nucleophiles, such as glutathione, 3-sulfanylhexanol and H2S, leads to the formation of additional products on different positions of the benzene ring [45], and such reactions should also prevent browning since the quinone is being quenched. There are also many technological solutions that when used can results in a more stable wine colour as, in white wines, a fast liquid/solid separation in the press machines, reducing phenolic acids by wine fining with PVPP, potassium caseinate/casein, isinglass, gelatine, patatin and pea protein. Winemakers need to be especially cautious when handling a cold wine, such as during cold stabilisation. Oxygen is more soluble at lower wine temperatures. However, the oxidation reaction speeds up when the temperature rises. As the cold wine warms up the greater amount of dissolved oxygen will contribute to serious wine oxidation. To minimise the adverse effects of oxidation during wine racking the winemakers employ several techniques such as, using SO2, using gentle pumps that minimise aeration, and checking hoses and fittings for leaks, and flushing hoses and containers with inert gas before wine racking. In modern winemaking, the inert gases are often used to minimise oxygen pickup in the head space of partially filled containers and during wine racking. The common inert gases used include; nitrogen, CO2, argon, and a mixture of these gases in various proportions. For economic reasons, the use of nitrogen and CO2 seems to be more common. To provide an inert gas cover over the wine surface in a partially filled container, CO2 or argon should be used. These gases are denser than the air and form an inert layer devoid of oxygen. The danger of oxygen exposure is greater during the wine racking. To minimise oxygen/air contact the system is purged with the inert gas. In the process of purging the inert gas is passed through the system such as hoses, transfer lines, equipment, and the receiving tank to displace air. The wine is then racked under an inert atmosphere.
The development of a salmon-red blush colour in white wines produced exclusively from white grape varieties is known as pinking, and the phenomenon is observed occasionally. It is perceived as an undesirable phenomenon by both wine consumers and the industry. Although with seasonal and regional variations, pinking has been observed worldwide, with predominance in white wines produced from V. vinifera L. grape varieties such as Chardonnay, Chenin Blanc, Crouchen, Muscat Gordo Blanco, Palomino, Riesling, Sauvignon Blanc, Sémillon, Sultana, and Thompson Seedless [46]. Pinking is mainly observed when white wines are produced under reducing conditions [47]. The pinking phenomenon is frequently observed after the bottling and storage of white wines or after alcoholic fermentation (AF) [48]. In wines made from Síria white grape variety, it was shown that the compounds responsible for the appearance of the salmon colour after bottling were due to the presence of small amounts of anthocyanins in the wine that could also be detected both in the pulp and in the skin of the white grapes [46].
Although it cannot be excluded that other compounds can be responsible for the appearance of a salmon colour in white wines from other grape varieties, the presence of the small number of anthocyanins in Chardonnay, Sauvignon Blanc, and Riesling has been shown [49]. To avoid the pinking problem there are various preventive or curative oenological treatments, including adding PVPP or PVPP associated with bentonite or increasing the redox potential using ascorbic acid in the pre-bottling stage [46].
Uncontrolled or undesirable microbiological activity developed in the wine can be responsible for several wine spoilage problems. These defects are diverse in origin and chemical compounds involved impact as well on the wine sensory quality.
One of the main problems that can occur is the development of high levels of volatile acidity, mainly acetic acid (I, Figure 1). Acetic acid can be formed at the beginning of wine production (in grapes), during fermentation, and in the bottled wine as a bacterial or yeast metabolite [50]. High volatile acidity is associated with bad SO2 management or extreme wine exposure to oxygen that stimulate the growth of aerobic acetic acid bacteria (AAB), that increases acetic acid. This results in an olfactory sensory defect known as vinegar off-odour. Vinegary wines are typically sharply acidic with an irritating odour. Ideally, the content of acetic acid should not exceed 0.7 g/L in wine. Several methodologies, aiming to decrease excessive volatile acidity of acidic wines have been proposed [50], such as microbial stabilisation of the acidic wine followed by blending with other wines, reverse osmosis, nano-filtration, and biological removal of acetic acid through refermentation [22].
Structure of the main wine off-odours and taints.
Acetaldehyde (ethanal) (II, Figure 1) in wine can impart some undesirable flavours, when above a certain level. The average values of acetaldehyde in white wine are about 80 mg/L, in red wine 30 mg/L and for Sherries wine 300 mg/L [51]. Acetaldehyde is an intermediate product of yeast fermentation; however, it is more commonly associated with ethanol oxidation, catalysed by the enzyme ethanol dehydrogenase. Moreover, acetaldehyde can be formed by non-enzymatic oxidation throughout the storage and ageing of wine [52]. During wine oxidation, iron (II) reduces oxygen to the hydroperoxyl radical, which converts wine ortho-diphenols phenols into quinones and H2O2. Ferrous ion associated with H2O2 generates hydroxyl radical that can react with ethanol to yield acetaldehyde [53]. The sensory threshold for acetaldehyde in red wines is typically in the range of 40–100 mg/L [54]. If present at low levels gives a pleasant fruity aroma, but at high levels, it possesses a pungent irritating odour [55]. Indeed, excess acetaldehyde produces a ‘green,’ ‘grassy,’ ‘nutty,’ ‘sherry-like,’ ‘bruised apple,’ or even ‘vegetative’ off-flavour [30, 56]. The level of acetaldehyde in wine can be reduced by appropriate yeast strain selection, as well as the prevention of oxidation during the winemaking process [57]. The reduction of acetaldehyde can also be done by wine lactic acid bacteria (LAB) of the genera Lactobacillus and Oenococcus which can degrade free and SO2-bound acetaldehyde [58]. Acetaldehyde also strongly binds to SO2, reducing the free acetaldehyde content, and thus the perception of its aroma in wines [2].
Diacetyl (2,3-butanedione, III in Figure 1), is usually found in low levels, as a result of yeast metabolism (<1 mg/L), but it is principally formed during malolactic fermentation (MLF), by the metabolism of citric acid, which is usually naturally present in wines at levels between 0.1–0.7 g/L [59]. If present in an excessive content sufficient to affect wine’s flavour, is usually considered as a fault, generating a buttery, nutty or toasty, lactic off-odour. The detection threshold for diacetyl in a 10% aqueous ethanol is 0.1 mg/L [11]. However, the diacetyl detection threshold is dependent on the wine matrix. It has been reported as 0.2 mg/L in white wine (Chardonnay) and from 0.9 mg/L (Pinot Noir) to 2.8 mg/L (Cabernet Sauvignon) in red wines [60]. Also, diacetyl quickly bounds SO2, and the free and bound forms of diacetyl are in chemical equilibrium, depending on the pH, the level of SO2, and the presence of other SO2 binding components, such as acetaldehyde, α-ketoglutaric acid, and pyruvic acid are important [61]. It is assumed that only the unbound form of diacetyl is sensorially active. According to Nielsen and Richelieu [61] the addition of 80 mg SO2, which is within the range used in the wine industry, reduced the free diacetyl content (20 mg/L) by 75%.
All wines contain a few tens of mg/L of ethyl acetate (30–60 mg/L, IV in Figure 1) produced by yeast, higher levels indicate AAB activity, formed by esterification between acetic acid and ethanol. This compound at low levels in wine (<50 mg/L) may not be unpleasant, contributing to ‘fruity’ aroma properties and add complexity to the wine, but at levels >150 mg/L ethyl acetate can confer an unpleasant ‘fingernail polish’ aroma [62]. Ethyl acetate has a perception threshold in the wine of around 160–180 mg/L, which is much lower than that of acetic acid (750 mg/L) [22]. The deleterious effect of ethyl acetate can be in part reduced by ageing [63] but, after 6 months of bottle ageing, the ethyl acetate levels (140–180 mg/L) affect the wine flavour, giving wines a hot flavour which reinforces the impression of bitterness on the aftertaste [22]. It is usually more perceived in white wine than red wines. Factors that can influence ethyl acetate formation include the yeast strain used during the AF as well as the temperature of fermentation and SO2 levels. Ethyl acetate is also produced by AAB and is related to dissolved oxygen levels in the wine [64].
Vinylphenols and ethylphenols are collectively known as volatile phenols (VPs). Vinylphenols (4-vinylphenol and 4-vinylguaiacol, V, and VI in Figure 1, respectively) are produced by the yeast S. cerevisiae, LAB such as L. plantarum, and Dekkera/Brettanomyces yeasts [65]. Their impact on wine quality is almost exclusively observed in white wines, as these wines can contain significant quantities of vinylphenols which, beyond a certain content (limit threshold = 725 μg/L of 4-vinylguaiacol+4-vinylphenol (1:1)), can be responsible for a depreciating ‘phenolic’ or ‘pharmaceutic’ characteristic [66]. S. cerevisiae possesses a cinnamate carboxylase enzyme which can transform by non-oxidative decarboxylation, the phenolic acids p-coumaric and ferulic acids, into corresponding vinylphenols. This activity is only expressed during AF and with a variable intensity depending on the yeast strain. Although Dekkera/Brettanomyces yeasts can also produce vinylphenols they are more likely to reduce the available vinylphenols to ethyl derivatives. It has been shown that Dekkera/Brettanomyces is the only known microorganism that under winemaking conditions can produce significant amounts of VPs [67]. The ethylphenols are formed by these yeasts through decarboxylation of the corresponding hydroxycinnamic acids to vinylphenols, and subsequent reduction to ethylphenols, yielding 4-ethylphenol (VII in Figure 1) from p-coumaric acid and 4-ethylguaiacol (VIII in Figure 1) from ferulic acid [67, 68]. Some attributes, such as animal, stable, horse sweat was designated by the widespread term ‘Brett-character’ in oenology [69]. The perception threshold of EPs (4-ethylphenols, designated as 4-ethylphenol and 4-ethylguaiacol) is influenced by the wine matrix. The values reported by Chatonnet et al. [68] 440 μg/L for 4-EP and 135 μg/L for 4-EG were found in a model solution. In red wines, the 4-ethylphenol presents a detection threshold of 230 μg/L [70] while the combination of 4-ethylphenol with 4-ethylguaiacol shows a threshold of 400 μg/L [68]. Nowadays, perhaps it is the most problematic sensory defect in red wine production around the world, with million litres being be contaminated each year [71]. In the last years, research has been performed to remove these negative VPs from contaminated red wines [67] and efficient treatments include activated carbons (ACs) and fungal chitosan to avoid the growth of contaminated yeast or to reduce the head space volatility of these negative VPs [3, 72]. New materials have been evaluated for their removal aiming to decrease the negative impact of the former treatments on wine quality. Of the new material that includes molecularly imprinted polymers [73], chitosan [3] and degassed and ethanol impregnated cork powder [74], that can remove about 70% of ethylphenols allowing a significant recovery of the wine’s fruit and floral character [74]. This material is cheap and easily prepared from cork powder wastes, being natural with good biodegradability, and low environmental impact.
The formation of mousy off-flavours can occur during (MLF) either by the action of LAB (particularly heterofermentative strains) or Dekkera/Brettanomyces yeast. This off-flavour can be associate to three compounds, namely the N – heterocyclic volatile bases 2-acetyltetrahydropyridine (sensory threshold in water =1.6 μg/L, IX, Figure 1), 2-ethyltetrahydropyridine (odour threshold in wine = 150 μg/L, X, Figure 1, [75] and 2-acetylpyrroline (detection threshold in water = 0.1 μg/L, XI, Figure 1, [76], being the first one produced at the highest levels. Dekkera/Brettanomyces are capable of producing at least two of these compounds, whereas LAB are capable to produce all the three [77]. Although the biosynthetic pathway for the mousy off-flavour compounds formation in wine is unknown, the conditions necessary for its production have been established.
Aroma properties evocative of rotten eggs, cabbage, garlic, putrefaction are termed ‘reduction’. These aroma attributes are generally considered to contribute negatively to overall wine sensory quality and are considered to be related to different low molecular weight volatile sulphur compounds, such as H2S, (odour threshold in red wine 1.1 μg/L), methyl mercaptan (methanethiol, odour threshold in red wine 1.8 μg/L, XII, Figure 1), ethyl mercaptan (ethanethiol, odour threshold in red wine 1.1 μg/L, XIII, Figure 1), and dimethyl sulphide (odour threshold in red wine 25 μg/L, XIV, Figure 1) [80]. Yeast fermentation is frequently associated with the occurrence of reductive off-odours, mainly linked to the formation of H2S and mercaptan by the yeast as mentioned by Pereira et al. [81]. As nitrogen availability is considered one of the main factors for H2S production by yeast, a strategy that could be adopted is the addition of yeast assimilable nitrogen to supplement fermentation [80]. The production of H2S during the AF is normal and the quantity produced is dependent on multifactorial factors such, yeast DNA, grape juice turbidity, level of assimilable nitrogen in the grape juice, levels of methionine and cysteine, fermentation temperature, high levels of SO2, and sulphates. This type of aroma sometimes masks completely the positive varietal and fermentative aroma, however, H2S is very volatile and usually, simple wine aeration is enough to remove them or can be precipitated with copper sulphate or copper citrate. The excessive aeration of the wine in the presence of H2S could lead, by oxidation, to the production of heavy thiols that could be exceedingly difficult to remove from the wine. On the other hand, mercaptans and the other sulphides, are more intractable. Mercaptans impart off-odours reminiscent of rotten onions and disulphides are formed under similar reductive conditions and generate cooked-cabbage odours. Related compounds, such as 2-mercaptoethanol (XV, Figure 1) and 4-(methyl thiol) butanol (XVI, Figure 1), produce intense barnyard and chive–garlic odours, respectively.
Light-struck refers to a reduced-sulphur odour that can develop in wine during exposure to light [62]. This defect is associated with the formation of volatile sulphur compounds with unpleasant aroma notes, formed by the methionine degradation catalysed by the photochemically activated riboflavin. Methanethiol (XII, Figure 1) and dimethyl disulphide (XVII, Figure 1) are the main compounds responsible for the light-struck taste in white wine termed as ‘cooked cabbage’ [82, 83]. Exposure of wine to light at wavelengths close to 370 or 442 nm is particularly effective in inducing the light-struck taste [84], manly when clear glass bottles are used [85]. The preventive strategies are the most efficient as this defect generally develops after wine bottling, and these are mainly related to the reduction of the riboflavin levels in grape juice and wine. There are classic and authorised fining agents, such as bentonite and AC (activated carbon) that can be used to remove with relative efficiency riboflavin from white wine [86]. After application, if bentonite the average residual riboflavin was 60% [86, 87]. Also during the AF, the selection of low riboflavin-producing yeasts can be used as it was shown that it is yeast strain-dependent [86, 87].
Several herbaceous off-odours may be detected in wines. The presence of excessive sensations of herbaceous off-odour results in a decrease in the fruit notes, normally not appreciated by consumers. The source of this off-odour can generally be due to the presence of alkylmethoxypyrazines or aldehydes and alcohols with C6. The main alkylmethoxypyrazines found in grapes, musts, and wines are 3-ethyl-2-methoxypyrazine (ETMP, XVIII, Figure 1); 3- sec-butyl-2-methoxypyrazine (SBMP, XIX, Figure 1); 3-isopropyl-2-methoxypyrazine (IPMP, XX, Figure 1); and 3- isobutyl-2-methoxypyrazine (IBMP, XXI, Figure 1), conferring aromatic notes described as ‘green pepper’, or ‘tomato leaf’. Alkylmethoxypyrazines represent a narrow, delineated group of extremely powerful odorants characterised by extremely low sensory perception thresholds (1–2 ng/L in distilled water [88]; being present in green plant tissues, including grapes [89]. The content of methoxypyrazine in the wine depends primarily on grape composition [90], being observed a complex relationship between viticultural practices and varietal aroma, being difficult to predict the final wine aroma because of the multiple compounds and pathways involved. This vegetative character is most commonly, although not exclusively, associated with Sauvignon Blanc, Cabernet Sauvignon, and other Bordeaux varietals [91]. IPMP may also be present in certain grapes and thus found in the derived wine as a varietal character. The excessive green bell pepper aroma found in red wines containing IBMP is generally considered unfavourable to wine quality. However, the presence of this compound at low levels is often noted to augment the quality of certain wines obtained from red varieties (Cabernet Franc, Cabernet Sauvignon, Carménère, Merlot) or white varieties (Sauvignon Blanc, Sémillon) by adding to the intrinsic flavour complexity of these varietals [92]. The presence of IBMP can be a positive quality factor when it is not dominant but is in balance and complemented by other herbaceous and fruity aromas [93].
Aldehydes and alcohols with 6 carbon atoms are volatile, odorous molecules that can contribute to the herbaceous aroma in the wine. Their cut-grass-like aroma is the characteristic odour of freshly damaged green leaves; therefore, these compounds are often referred to as green leaf volatiles [94] and may also impart a bitter flavour [95]. The C6 alcohols frequently found in grapes include hexanol (XXII, Figure 1), (Z)-3-hexenol (XXIII, Figure 1), and (E)-2-hexenol (XXIV, Figure 1). (E)-2-hexenol, (E)-3-hexenol may also be found in wine at levels of μg/L [96]. The C6 aldehydes commonly identified in grapes are hexanal (XXV, Figure 1) and (E)-2-hexenal (XXVI, Figure 1); also C7 aldehydes have been found, but at lower content concerning C6 aldehydes [97]. At low levels (< 0.5 mg/L threshold), these C6 volatiles compounds contribute positively to the overall aroma of the wine. These C6 compounds may be present in a free volatile form or in bound form, as glycosides [98]. They are mainly generated through the enzymatic breakdown of C18 polyunsaturated fatty acids contained in plant membranes. The C6 aldehydes and alcohols derive from the oxidation of grape polyunsaturated fatty acids such as oleic acid, linoleic acid, and linolenic acid initiated by the lipoxygenase pathway when the berries are crushed [99]. Their levels in must can be in the order of several hundreds of μg/L [100] or even more than 13,000 μg/L [101], with very variable odour thresholds (400–8000 μg/L) [11]. Their levels depend on several factors, including the grape variety and ripeness, treatments before fermentation, and temperature/duration of contact with the skins.
1,1,6- trimethyl-1,2-dihydronaphthalene (TDN, XXVII, Figure 1) exhibits kerosene- and petrol-like off-flavour when present at high levels. Precursors of TDN are carotenoid derived compounds originating from the grapes [102]. These precursors are slowly converted to TDN in the wine acidic medium. Kerosene/petrol aroma usually becomes perceivable after several years of wine storage. TDN is an ambiguous aroma compound, defining the varietal character of Riesling wine but also constituting a repelling taint [103] Comparing wines made of various grape varieties, a perceivable amount of TDN is found mostly in Riesling wines. The recognition threshold of TDN has been reported by Simpson [104] to be in the range of 20 μg/L, while Sacks et al. [105] determined a detection threshold of 2 μg/L. Exposing the grapes to more sunlight by defoliation increases both TDN levels [106]. Low pH and bottle ageing will increase their content likewise due to hydrolytic cleavage of the TDN precursors [102, 106].
1,8-Cineole (eucalyptol, XXVIII, Figure 1) is known to give the perception of eucalyptus and minty flavour, not negative sensory notes by themselves, the reason why there is a discussion if it should be considered as a positive or as a taint in red wine. The sensory perception threshold is very low, of 1.1 μg/L, and a recognition threshold of 3.2 μg/L in Californian Merlot wine [107]. Farina et al. [108] reported similar threshold values in Uruguayan Tannat wine. According to Saliba et al. [109], the mechanism by which 1,8-cineole occurs in the finished wine is not well understood and three mechanisms have been suggested: the compound develops from chemical precursors during the winemaking and bottle ageing processes, namely by chemical transformation of limonene and α-terpineol [108]; that grapes naturally produce the compound during berry development [110]; 1,8-cineole is introduced via another source for example from trees.
Geranium taint is due to the presence of 2-ethoxy-3,5-hexadiene (XXIX, Figure 1) in wine, which has an odour reminiscent of crushed geranium leaves. It is originated from the reduction of sorbic acid carried out by the LAB. The reduction product sorbitol under wine conditions isomerises to 3,5-hexadiene-2-ol that after reaction with ethanol generates the 2-ethoxyhexa-3,5-diene which has a sensory threshold of about 0.1 mg/L [111].
Grapevines and grape exposure to smoke from firers can result in wines with undesirable sensory characters, such as ‘smoky’, ‘burnt’, ‘ashy’ or ‘medicinal’, usually described as ‘smoke taint’. Smoke taint markers in grapes and wine are the VPs, guaiacol (XXX, Figure 1), and 4-methylguaiacol (XXXI, Figure 1) [112]. Kennison et al. [113], showed that trace levels (≤1 μg/L) of guaiacol, 4-methylguaiacol, 4-ethylguaiacol and 4-ethylphenol were detected in grape juice derived from grapes harvested from grapevines exposed to smoke; but significant quantities of these phenols were released when the grape juice was fermented, or hydrolysed with strong acid or β-glucosidase enzymes. These compounds are known to exhibit ‘smoky’, ‘phenolish’, ‘sharp’, and ‘sweet’ aromas [113]. Guaiacol causes a phenolic and medicinal taint in a contaminated wine [114], its flavour threshold is 0.030 mg/L in an aqueous solution containing 12% ethanol. An aroma threshold of 0.020 mg/L in a dry white wine was reported by Simpson et al. [115] and a detection threshold in the water of 5.5 μg/L and white wine of 95 μg/L and red wine, 75 μg/L [112].
2,4,6-trichloroanisole (TCA, XXXII, Figure 1) is probably the most known compound associated with wine defect, being the key compound responsible for the ‘cork taint’ in wines [116]. It is very easy to recognise because of its low sensory threshold, which is from 0.03 to 1–2 ng/L in water and 4 ng/L in white wine for trained assessors. However, the threshold values in wine depend strongly on the kind of wine, the wine style, and the experience of the panellist [117]. ‘Cork taint’ is mostly described as a musty, mouldy, or earthy smell, being sometimes also described as burnt rubber, smoky or even camphor. Other chloroanisoles, such as 2,4-dichloroanisole (2,4-DCA, XXXIII, Figure 1), 2,6-dichloroanisole (2,6-DCA, XXXIV, Figure 1), 2,3,4,6-tetrachloroanisole (TeCA, XXXV, Figure 1) and pentachloroanisole (PCA, XXXVI, Figure 1) can also contribute to the ‘cork taint’ but they do not play a dominant role in this fault. 2,4,6-tribromoanisole (TBA, XVII, Figure 1) can also have a significant role in the musty/mouldy of-odour of wines [118]. Moreover, the aroma masking effect of TCA or TBA can be perceived in the wines at levels even lower than perception thresholds (4 ng/L) [118]. As cork is a natural product from the cork oak it is subject to microbial contamination and its quality is dependent on good agricultural practices and quality control during processing, transport, and storage. Chlorophenolic biocides (nowadays forbidden but accumulated in the environment) are the common precursors which can be transformed by certain fungi to TCA and different chloroanisoles. Other pathways of chloroanisoles formation usually include reactions of chlorination and methylation of compounds naturally present in wooden and cork materials [119]. At the same time 2,4,6-tribromophenol (TBP), which application is not restricted present, can play the role of TBA precursor and increases the risk of musty/mouldy taint in wines [118]. Moulds are considered the most significant causative organisms of cork taint, with implicated genera including Penicillium, Aspergillus, Cladosporium, Monilia, Paecilomyces and Trichoderma. Nevertheless, the process of wine contamination by haloanisoles is complex. Since cork stoppers are the most known source of these compounds, the musty/mouldy fault was named ‘cork taint’. However, succeeding studies demonstrated that musty/mouldy defects in wine are not originated exclusively from the naturally contaminated cork materials [118, 120]. TCA and other haloanisoles can be formed in different wooden parts inside the cellar (barrels, ceiling constructions, pallets) and subsequently released into the air. Hereafter, the contamination of winery equipment and ‘clean’ cork stoppers occurs and haloanisoles can be transmitted further to the wine. Besides, cork taint-related flavours were found in wines that were barrel samples or not closed with natural cork stoppers, indicating that natural cork stoppers are not the only source of mouldy off-flavours [118, 120]. Therefore, depending on the compound causing the cork taint, the consumer has a different impression of the problem. Several compounds with similar negative flavour attributes were discovered in mouldy and musty smelling wines that were not affected by TCA (geosmin, 2-methyl-isoborneol, octane-3-one, pyrazines, etc.) [121]. That said, misguided hygiene practices have historically been part of the cork-taint problem. Cleaning using chlorinated bleach was common in wineries until a link to cork taint was found. Contact between barrels and bleach on cellar floors was a particular pathway for TCA to strike. Flame-retardant paints and fungicides were found to taint wine with TBA. Barrelled wines were particularly badly hit, and some facilities had to be rebuilt. Nowadays most wineries know to avoid chemicals containing tribromophenols. Heat-treated wood is more common, and barrels are rarely cleaned with chlorine. Different approaches were made regarding the removal of TCA and TBA from tainted wines; either by fining with ACs and filtered afterwards, or polyethylene was added as an adsorbent to the wine [121].
Along with TCA and TBA, geosmin (XXXVIII, Figure 1), 2-methylisoborneol (MIB XXXIX, Figure 1), 1-octen-3-one (XL, Figure 1) and 1-octen-3-ol (XLI, Figure 1) are compounds that are closely linked with the growth of moulds [116]. Their presence in wines can impart typical earth, mushroom, fungal and mouldy flavour [122, 123]. The mushroom aroma is associated mainly with 1-octen-3-one and 1-octen-3-ol, whereas the earthy aroma is attributed to (−)-geosmin and an earthy-camphor aroma to 2-methylisoborneol. Geosmin may result from the development in grapes picked in unfavourable weather conditions by microorganisms. It is a chiral compound and the (−) form is much more odoriferous than the (+) form. (−) Geosmin is also the only enantiomer to have been identified in pure cultures of Streptomyces sp. and Penicillium sp. strains isolated from rotten grapes [121]. Geosmin olfactory detection threshold depends on the wine matrix: In water: 10 ng/L [122]; In wine: white wine, 60–65 ng/L [122]; red wine, 80–90 ng/L [122]. MIB is a metabolite of Botrytis cinerea, some Penicillium spp. and some Streptomyces spp. MIB and 1-octen-3-one have also been found in musts made from rotten grapes but not in the corresponding wines, indicating that they are not stable during AF [123]. The findings of both compounds in bottled wine can therefore be linked to the cork stopper and the growing of mould on the cork during the manufacturing process. MIB olfactory detection threshold has been determined as: 0.012 μg/L (in water La Guerche et al. [123]; 0.04 μg/L [123]; in red wine). 1-octen-3-ol (olfactory detection threshold in the water of 2 μg/L and red wine, 40 μg/L, La Guerche et al. [123], however, has also been found on rotten grapes and the musts made from them and is stable during AF so that an occurrence of this compound in a wine can be caused by mould growth on the grapes as well as by contaminated cork stoppers [124]. Lisanti et al. [125] showed that in the red wine the potassium caseinate and grape seed oil treatments decreased the level of geosmin by 14% and 83%, respectively, while in the white wine, the AC and the grape seed oil were able to decrease the level of geosmin by 23% and 81%, respectively. However, after estimating the olfactory impact of the volatile compounds by OAVs (concentration/odour perception threshold), only the treatment with grape seed oil was able to decrease the relative contribution of geosmin in the profile of the odour active compounds, in both wines.
Wine can accidentally be contaminated with styrene when trace amounts of the styrene (XLII, Figure 1) are released during wine storage in polyester tanks reinforced with fibre glass [126]. Also, occasionally styrene contamination has been detected in wine in contact with synthetic closures [127]. The taste threshold for styrene in water has been reported as 22 μg/L [128] but may be higher in wine. An amount higher than 100 μg/L (the generally accepted threshold of sensory perception), styrene can modify the wine sensory characteristics by imparting a taste of plastic and adhesive. Wagner et al. [129] found in German wines values ranging from 0 to 19 μg/L.
The wine imbalances by acidity, astringency, or bitterness, are often the first defects noted in the sensory perception of wine quality [13].
Organic acids are the main responsible for sourness and able of modifying this sourness sensation in wines producing a pleasant and refreshing sensation [130]. However, when present at high levels they are responsible for an unpleasant acidity. Therefore, it is generally accepted that too much acidity will taste excessively sour and sharp, while wines with too little acidity will taste flabby and flat and present a less defined flavour profile [131]. Organic acids contribute to the tartness and mouth-feel properties of wine. Tartaric acid is the main organic acid in wine, which, at high levels (>5 g/L), is responsible for an unpleasant taste. Other acids include malic, citric, fumaric, succinic, pyruvic, α-ketoglutaric, lactic, and acetic [3]. However, different organic acids have different sensory properties, and the impact of organic acids is therefore not only linked to total acidity and pH, but to the specific levels of each acid in the wine [132]. The perceived sourness was imparted by L-tartaric acid, D-galacturonic acid, acetic acid, succinic acid, L-malic acid, and L-lactic acid and was slightly suppressed by the levels of chlorides of potassium, magnesium, and ammonium [16]. Acidity adjustment is the reduction or increase in titratable acidity so that the resulting wine will be acceptable. Acidity adjustment can be performed by the addition of an approved acid, the chemical deacidification with approved salts, and using ion exchange resins, either cation, anion or both, electromembrane processes and by biological deacidification. Tartaric acid is commonly used to increase the titratable acidity and reduce the pH in the wine industry, because of its stability and the fact that yeast and other microorganisms are unable to metabolise it at wine pH [133].
The reduction of titratable acidity by the addition of carbonate salts such as calcium carbonate, can be done in one of two ways, the first, is a direct addition which is not recommended as it results in wines which are unstable with respect to calcium tartrate, the second is to treat only a wine portion. This process causes the pH to increase up increase to 4 or 4.5 at the end of the addition. The tartaric and malic acids are primarily in the ionised forms. The precipitation of their calcium salts is favoured and this also lowers the calcium levels. This method is referred to as the double-salt and it may be used to reduce the total acidity of high-acid grape musts before fermentation. The precipitation is primarily that of calcium tartrate and under certain circumstances the coprecipitation of calcium malate [2]. Ion exchange resins, either cation exchange alone or as a combination of anion and cation exchange, can also be used to change wine acidity [19]. In red wine for example the acid reduction can be achieved by using LAB strains. MLF refers to the conversion of malic acid to lactic acid and CO2. This secondary fermentation usually takes place after the AF. The benefits of MLF is the acidity reduction and simultaneously add the complexity of aroma and taste and provides a more microbiological stable wine [2].
One of the most important sensations and a quality attribute is astringency. Gawel et al. [134] presented a structured vocabulary derived by a panel of experienced wine tasters that describe the astringent sub-qualities of red wines, such as velvety, drying, puckering, or roughing. Astringency is mainly a tactile sensation [135] not a taste because it can be perceived in regions of the oral cavity where there is no taste receptor [96, 136, 137]. The major mechanism proposed to astringency perception is the interaction and precipitation of salivary glycoproteins, namely by tannins generating a loss of lubrication [136]. Vidal et al. [138] showed in model solutions that astringency perception of proanthocyanidins increases with their mean degree of polymerisation (mDP) and their percentage of galloylation [139]. Oligomeric proanthocyanidins have been described as inducing lower roughness than the more polymerised molecules, whereas an increase in galloylation has been associated with a higher perceived drying and roughing astringency [139]. However, other wine phenolic compounds, such as flavonols, phenolic acids, or anthocyanins, can also play an important role in astringency development [139].
Bitter perception in wines is related to phenolic compounds with low molecular weights as well as to monomeric or small phenolic flavanols [16]. Concerning the latter, they have been described for a long time as the main contributors to the bitterness generated by flavonoid phenols [140]. Monomeric flavonoid phenols are primarily bitter but as the molecular weight increases upon polymerisation, astringency increases more rapidly than bitterness. It has also been shown that chiral difference between the two major wine monomeric flavanols produces a significant difference in temporal perception of bitterness: (−)-epicatechin is significantly bitterer and has a significantly longer duration of bitterness in the mouth than (+)-catechin [140].
Protein fining agents could induce some sensory changes. Astringency and bitterness of wine can decline due to its interaction with tannins. The fining process directly occurs from the precipitation of proanthocyanidins by these protein fining agents and it is influenced by the chemical characteristics of the protein used. The interactions between proanthocyanidins and protein fining agents depend on molecular weight, amino acid composition and surface charge density of the proteins used [141, 142, 143, 144].
Different proteins are used for wine fining such as gelatine, egg albumin, isinglass, and casein/potassium caseinate. Different types of gelatine remove different amounts of proanthocyanidins (9–16%) depending on the wine phenolic composition and structural characteristics of the proanthocyanidins and on the gelatine composition and characteristics [142, 143]. It has been generally thought that proteins bind primarily high polymerised tannins as well as high galloylated tannins, and therefore are preferentially removed [141], but some recent work showed that each of the different proteins (gelatine, egg albumin, isinglass, casein) and different size fractions of the same protein class interact differentially with different sizes of tannins [142, 143]. Regardless, allergen labelling may make wine fining with any of the animal-derived products impractical although some effort has been made to evaluate plant-derived proteins [144]. Recent studies of wine astringency demonstrated that tannins must be different two-fold for a trained panel to be able to successfully differentiate the wines [145]. Further, since some of the polymeric pigments can precipitate with protein there is the risk of losing stable colour [146]. As mentioned previously a higher astringency intensity is directly associated with a higher concentration of proanthocyanidins with a higher mean degree of polymerisation [147]. During ageing, astringency perception becomes softer, the reasons for the change in wine astringency could involve a decrease in proanthocyanidin concentration accompanied by a decrease in proanthocyanidins structural changes [148].
Therefore, the phenolic composition could be modulated during the winemaking steps (maceration/fermentation, stabilisation (fining) and ageing) and consequently, it allows the modulation of wine astringency and/or astringency sub-qualities as well as the wine bitterness.
In fermented beverages in which a variety of microorganisms exist it may be inevitably the production of toxic products as a result of their metabolism and side reactions, including ethyl carbamate (I, Figure 2), biogenic amines (II, Figure 2) mycotoxins, namely ochratoxin A (III, Figure 2) and aflatoxin B1 (IV, Figure 2). They are generally generated due to the incomplete metabolism of nitrogen-containing compounds during the fermentation process [149].
Main wine potentially toxic compounds. (I) EC; (II) BAs – (a) histamine; (b) tryptamine; (c) phenylethylamine; (d) tyramine; (e) putrescine; (f) cadaverine; (g) agmatine; (h) spermine; (i) spermidine; (j) methylamine; (k) dimethylamine; (m) ethylamine; (i) isopentylamine; (III) OTA; (IV) AB1.
Ethyl carbamate (EC), also known as urethane, is an ethyl ester of carbamic acid that can be found in several fermented beverages [150] including wines [151]. EC levels in wines can range from n.d.-19 μg/L in white wine, n.d.-54 μg/L in red wine, 14–50 μg/L in fortified wine, and n.d.-58 μg/L in sherry-type wine [152]. EC is classified as a ‘probable human carcinogen’ by the IARC since 2007 (group 2A) [153]. Although currently there is no harmonised maximum level for EC, some countries have established their criteria for example in Canada the maximum level is 30 μg/L for wine, the Canadian guidelines were adopted by other countries such as Czech Republic, Brazil, France, Germany, and Switzerland. South Korea also set the maximum limit of 30 μg/L only for table wine. For fortified wine, the maximum level of EC is 100 μg/L in Canada and the Czech Republic, and of 60 μg/L in the US [154]. EC can be produced from at least five precursors, namely urea, citrulline, carbamyl phosphate, cyanic acid and diethyl pyrocarbonate. In turn, urea and citrulline can be respectively generated by yeast and LAB by metabolisation of arginine, a major amino acid found in grape juice and wine [155]. The fermentation conditions, such as pH, temperature, ethanol level, light irradiation, oxygen, storage time, yeast or LAB strains can also affect the formation of EC [156]. For example, lowering the temperature during fermentation and storage, lowering the pH, lowering the ethanol content, and addition of diammonium phosphate as a yeast nutritional supplement reduces the EC concentration. The development of techniques for EC elimination from alcoholic beverages [155] has attracted considerable attention, and enzymatic decomposition methods have been widely employed given their safety and environmentally friendly nature. Two enzymes are used, namely, urease, which is commercially available and can degrade urea, the major precursor of EC [157], and urethanase, which can directly catalyse EC degradation [158]. To reduce EC concentration in wine, the use of acid urease seems to be the most appropriate way to suppress EC formation [19, 159]. Moreover, the efficiency of commercial acid urease treatment varies with several factors, including pH, temperature, the presence, and concentration of inhibitors (malate, ethanol, phenolic compounds), and type of wine [157]. Therefore, the immobilisation of acid urease in chitosan beads enhances the protection against inhibitors, increases the stability of the enzyme, and has the advantage of facilitating enzyme recycling and consequently reducing the cost of its use. EC content can also be effectively reduced by decreasing the generation of its precursors. Significant advances have been made via genetic technologies in modifying fermentation strains that produce less EC precursors. Genetic modification approaches have the potential to provide safe, affordable, and effective methods to decrease EC formation. Several studies have shown that the modification of catalytic enzymes, such as urea carboxylase, arginase, and allophanate hydrolase, showed the ability to reduce the concentration of EC [156]. Additionally, the modification of urea permease and amino acid permease, which are regulated by several factors and directly affect the generation of EC precursors have been explored [160]. Since the metabolism pathways related to urea have been fully considered for the high-efficiency minimisation of EC, enhancing the gene expression of DUR1,2 and DUR3, which encode urea degradation enzymes and permease, respectively, is considered to be a viable strategy. In this way, the modification of permease has led to the construction of functionally enhanced urea-importing wine yeast cells, which can continuously express the DUR3 gene and reduce EC level in Chardonnay wine by 81% [161].
Biogenic amines (BAs) are low molecular weight organic bases that have adverse physiological effects on humans when absorbed at high levels [162]. BAs are formed by decarboxylation of the corresponding amino acids by microorganisms such as LAB [162]. Pediococcus, as well as Lactobacillus, have been implicated in the production of BAs in wines that have undergone spontaneous MLF [162]. The final BAs levels in wine depend on the availability of the precursor amino acids and the BAs producing bacteria [162]. The only currently available simple and efficient solution to avoid or minimise BAs formation in wine is the use of MLF starter cultures [163]. After inoculation, the selected strain becomes dominant during MLF. Another recommendation is to avoid the practices that increase amino acid and peptide levels in musts. This also implies that LAB have more substrates, not only for producing BAs but also to survive better and longer after MLF [164]. Although there are currently no official values for the maximum limits for histamine and other BAs, the maximum value imposed for the levels of histamine, has been established through wine purchase and sale contracts, with the German companies demanding a maximum level of 2 mg/L of histamine. For these reasons, strategies for the reduction/elimination of BAs in wine are necessary, especially histamine. Until now, there are not useful treatments for reducing BAs levels especially, in red wines. However, it has been shown that uncommon wine LAB strains have amine oxidase activities that degrade histamine, tyrosine, and putrescine [165]. Also, non-Saccharomyces yeasts, such as Schizosaccharomyces, can decrease malic acid content in wine, they can be an excellent alternative to LAB, avoiding the MLF. Also, the use of Schizosaccharomyces reduces the risk of BAs production [166]. According to the OIV Resolution [19], only bentonite is applied in already contaminated wines to reduce the content of the BAs in the final wine [167]. Bentonite has a negative surface charge density, being able to exchange the cations adsorbed on its surface by the wine BAs. However, due to the negative impact on wine aroma combined with the high wine losses due to the high volume of lees, bentonite is presently not an adequate solution and other options need to be studied. Till now, there is no effective way of removing BAs in the finished wine.
Mycotoxins are secondary metabolites produced by several fungi that grow in food, including wine, under particular circumstances, with ochratoxin A (OTA) being one of the most important [168]. In 1993, the International Agency for Research on Cancer (IARC) classified OTA as possibly carcinogenic for humans (group 2B) [169]. Since 2006, the maximum limit for OTA in wine is 2 μg/kg [170]. OTA has been related to wine contaminations since 1996 [171] and after that, the occurrence of OTA in wine samples has been described in several works. Blesa et al. [172] found an OTA incidence in wines of 53% in 521 red wines, 69% in 98 rosé wines, and 61% in 301 white wines. These data show that it is important to prevent and control the occurrence of this mycotoxin in wines. To eliminate this toxin, several chemicals, microbiological and physical methods have been described [168]. Nevertheless, in the case of wines, effective removal processes are limited, and at present, the use of adsorbents is the most common. OTA content can reduce in the final wine from 70 to 32% by fermenting with selected yeast [173], Non-Saccharomyces, such as Schizosaccharomyces, are also promising in reducing the OTA content by about 70% during fermentation [173]. Several fining agents have been evaluated concerning their ability to remove OTA from wines, and it was found that AC presented a good adsorption capacity for OTA [174]. Filtration before bottling about 0.45 μm of wine can easily reduce the final content in OTA by about 80% [174], but none of them is 100% efficient in removing OTA from wines.
Aflatoxins are a group of highly toxic secondary metabolites produced by fungi of the genus Aspergillus [175]. AFB1 is the most predominant and toxic aflatoxin. It is classified as a Group 1 human carcinogen (IARC) [169]. Aflatoxins and Aflatoxins-producing strains [176] have been detected in grape and musts [177]. The presence of aAFB1 in wines is caused by fungi that grow on grapes in the vineyards. In the literature, there are few studies regarding aflatoxins contamination in wines [177]. One of them is from Di Stefano et al. [178] that studied the occurrence of aflatoxins in 30 sweet wines from five winemaking in the Sicilian regions, Italy. The presence of aflatoxin in wines has been documented in recent years, largely because of the adaptability of aflatoxigenic fungi, such as A. flavus. At present, the EU has not set a maximum allowable limit for aflatoxins in wine, but this does not mean that the problem can be ignored. Therefore, it is essential to develop technological solutions to reduce/eliminate the levels of aflatoxins in wines. Recently the work from Cosme et al. [179] shows the high efficiency of bentonite in the removal of aflatoxin B1 and B2.
As overviewed in this chapter, there are many physicochemical wine instabilities and defects that can appear during wine production. Some defects can significantly decrease the wine’s sensory quality. However, today, there are several treatments and solutions to avoid them or reduce their impact on wine quality. The best strategy is always a preventive approach. Nevertheless, some of the defects are intrinsic to the grape composition and/or wine production process therefore they must be removed or minimised before bottling. The available treatments, either by using fining agents, additives, or other technological solutions, are generally effective, although they are sometimes not the perfect solution as they can also impact on positive wine sensory attributes and/or have a detrimental environmental impact. Current research trend is focused on the development of fining agents, additives, or technological solutions with improved specificity that will allow the removal of the defect without changing the other wine characteristics, and at the same time to explore low cost, natural or renewable materials that will allow a lower environmental impact of the stabilisation process.
To maintain hemostasis, new blood cells must be constantly generated to replace those lost through injury, disease, or age. Hematopoiesis, is the process where hematopoietic stem cells (HSC) differentiate into mature blood cells and is tightly regulated by the bone marrow (BM) micro-environment (or stem cell niche; reviewed in [1]), signal transduction pathways (reviewed in [2]), cytokines (reviewed in [3]), transcription factors (reviewed in [4]), epigenetics, (reviewed in [5]) and metabolic pathways (reviewed in [6]). HSCs are rare, constituting only 0.001% of peripheral blood (PB) and 0.05% of BM cells, but are responsible for producing a lifetime supply of blood cells. HSCs are cells that able to durably self-renew whilst also being multipotent. This differentiation is generally considered to occur via several intermediate progenitor cells, ultimately terminating in the specific mature blood cell through a process termed fate restriction or lineage commitment.
\nThe compartmentalization of HSC, their progenitors and terminally differentiated blood cells, into different stages of differentiation, is traditionally based on the expression of cell surface proteins (Figure 1). The recent emergence of single cell technologies such as fluorescent in situ hybridization, high-throughput single-cell quantitative PCR, single cell mass spectrometry and mass cytometry however, have led to re-analysis of these models of hematopoietic differentiation [7]. Discrete progenitor cell populations, as determined by cell surface markers, have been shown to consist of heterogenous populations with different fates [8]. Recently, a study by Velten et al., 2017, using a combination of single cell technologies and xenotransplantation as functional validation, proposed that early hematopoiesis consists of, a cellular continuum of low-primed undifferentiated (CLOUD) hematopoietic stem progenitor cells (HSPC), with simultaneous lineage gene expression for multiple fates [9]. This study suggested that early discrete stable progenitors do not exist, with any lineage determination occurring further downstream than originally presumed.
\nHuman hematopoiesis. Schematic diagram showing classical model of hematopoietic lineage commitment, with phenotypical cell surface markers (red), transcription factors determining differentiation (green box) and growth factors involved in myelopoiesis (blue). Hematopoietic stem cell (HSC), cluster of differentiation (CD), hematopoietic progenitor cell (HPC), common myeloid progenitor (CMP), common lymphoid progenitor (CLP), interleukin (IL), granulocyte macrophage (GM) colony-stimulating-factor (CSF), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), granulocyte myeloid progenitor (GMP), runt-related transcription factor 1 (RUNX1), transcription factor stem cell leukemia (SCL), ccaat enhancer binding proteins (C/EBP), friend of GATA protein 1 (FOG-1).
Regardless of provenance, leukemogenesis is characterized by a block in differentiation and an accumulation of immature white blood cell blasts with a rapid increase in these blasts, characteristic of the acute leukemias. Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are heterogenous diseases with a block in lymphoid or myeloid differentiation, respectively. They occur due to one or more genetic insults. Whilst ALL is predominantly a disease of children (80%), with a greater than 90% 5 y survival rate [10], in adults long term survival stands at only 30–40% [11]. AML in contrast is primarily a disease of the elderly, and like adult ALL it’s 5 y survival rate is around 30%, however this falls in the over 60’s to a particularly bleak 10% [12]. In ALL, recent advances for example in the use of tyrosine kinase inhibitors and CAR-T cell therapy, have started to suggest improvements to overall survival [10]. However, in patients fit enough to tolerate chemotherapy, the standard treatment for AML since 1973 has been a seven-day continuous intravenous infusion of cytarabine (Ara-C) (100–200 mg/m2) and 3 daily doses of daunorubicin (45–90 mg/m2), sometimes followed by allogeneic or autologous stem cell transplantation, and despite some recent advances (reviewed in [13, 14]), current treatments appear to have reached their efficacious limits and new therapies are required.
\nOne potential therapeutic opportunity involves exploiting the metabolic differences that exist between malignant and non-malignant cells [15]. Differences that, in AML at least, appear exacerbated by cellular levels of reactive oxygen species (ROS) [16].
\nROS is the collective term for several oxygen containing free radicals and other reactive molecules, such as hydrogen peroxide (H2O2). Physiologically, ROS are initially generated via the univalent reduction of molecular oxygen which generates superoxide (O2•−). Superoxide (t1/2 = 1 μs) subsequently dismutates to H2O2 (t1/2 = 1 ms) [17], either spontaneously or via the catalytic action of the enzyme superoxide dismutase (SOD), or reacts with other ROS molecules, forming a variety of other ROS (Figure 2). Functionally, ROS is important in innate immunity, protein folding in the endoplasmic reticulum and as a cell signalling molecule involved in cellular proliferation, survival, differentiation and gene expression [18].
\nFormation of reactive oxygen species (ROS). Diatomic oxygen (O2) is univalently reduced by peroxisomes (PO), xanthine oxidase (XO), the electron transport chain (ETC), or NADPH oxidase (NOX) to generate superoxide (O2\n•−). PO may also reduce O2 directly to form H2O2. O2\n•− may then dismutate to H2O2 either spontaneously or through the enzymatic action of superoxide dismutase (SOD). Hydroxyl radicals (OH•) may then be formed from H2O2 via the formation of hypochlorous radical (HOCl) in the PO, or via Fenton chemistry. Reactive nitrogen species (RNS) may also be formed through the reaction of nitric oxide radical (NO•) with O2\n•−.
There are several sources of cellular ROS, including the mitochondria, the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes (NOX), the cytochrome P450 enzymes, peroxisomes and the metabolic enzyme xanthine oxidase (XO).
\nGeneration of ROS by the mitochondria is primarily a function of ‘electron leakage’ from the electron transport chain (ETC), however, mitochondrial ROS may also be generated as a result of numerous enzymes including monoamine oxidase, cytochrome b5 reductase, glycerol-3-phosphate dehydrogenase, aconitase, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (reviewed in [19]). Mitochondrial ROS production resulting from the ETC generates O2\n•−, and is thought to occur as result of one of three mechanisms. The first mechanism is a consequence of a high NADH/NAD+ ratio, and results from oxygen interacting with fully reduced FMN. Mitochondrial ROS generated by this mechanism has been observed due to mitochondrial mutation, physiological damage such as ischemia or aging, and only small amounts of ROS are thought to be generated via these mechanisms in normally respiring cells [20]. The second mechanism occurs when there is a high level of reduced co-enzyme Q (CoQH2) in complex II, which in the presence of a high proton motive force generated by the proton pump, force electrons back into complex I in a process known as reverse electron transport (RET). Whilst RET generated ROS has also been implicated in diseases such as ischemia, it is now also thought to be involved as a cell signalling molecule in metabolic adaptation, myeloid differentiation and response to bacterial infection [21]. The third mechanism of ROS generation by the ETC occurs at complex III and has also been implicated in ROS signalling. The formation of O2\n•− occurs at the ubiquinol oxidation centre (Qo) site of the cytochrome bc1 complex, in which fully oxidized CoQ supports formation of O2\n•−, through the transfer of electrons from reduced heme b1 to molecular oxygen [22]. Generation of O2\n•− by complex I and II occurs exclusively in the mitochondrial matrix, whereas O2\n•− generated by complex III also occurs in the intermembrane space. O2\n•− generated in the mitochondrial matrix is rapidly converted to H2O2 by mitochondrial SOD (Mn-SOD), whereas O2\n•− generated in the intermembrane space travels through the outer mitochondrial membrane prior to conversion to H2O2 by cytosolic SOD (Cu/Zn-SOD).
\nWhilst mitochondrial oxidative phosphorylation is a major source of intracellular ROS, the main source of extracellular ROS involves the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes (NOX). The NOX family of enzymes comprise of seven members, NOX1–5 and dual oxidase (DUOX) 1 and 2. NOX enzymes are transmembrane proteins that transfer electrons from NADPH to molecular oxygen, generating O2\n•− (or H2O2), which can then be converted to other forms of ROS. Different NOX isoforms share conserved structural features comprising of six helical transmembrane domains (TM) (with helix III and helix V containing two heme-binding histidines), and a C-terminus cytosolic domain (DH), which allows binding of FAD and NADPH (Figure 3). Difficulties in obtaining suitable levels of NOX proteins mean that to date relatively little crystal structure data is available. However, a recently published report [23], has elucidated the structure of the TM and DH domains (common to all NOX isoforms) of Cylindrospermum stagnale NOX5 in complex with FAD. In this structure, the six transmembrane helices of TM domain form a pyramidal shape with the base on the cytosolic side, a N-terminus α-helix runs parallel to the cytosolic side of the membrane and the heme groups sit in cavities formed by helices II–V, so that one is positioned near the cytosolic side of the membrane (heme 1) and the other on the outer side (heme 2). The DH domain, located on the cytosolic side, contains two pockets, one for FAD binding and one for NADPH binding. The FAD is positioned so that the flavin is in direct contact with heme 1 of the TM, to promote interdomain electron transfer. The proposed mechanism of electron transfer then involves NADPH donating its electron to FAD, which in turn donates an electron to heme 1 and then to heme 2 via Trp378 (equating to Phe 215 in human NOX2, Phe 200 in human NOX4 and Val 362 in human NOX5) of the loop between helix II and III of the TM, before reduction of molecular oxygen, via a final electron transfer step generates O2\n•− (Figure 3).
\nGeneration of superoxide (O2\n•−) by NADPH Oxidase (NOX). Schematic diagram showing the major structural features of NOX2, it’s activation by phosphorylation (P) of p67phoxand p47phox and the assembly of the major subunits of the NOX complex, and the generation of superoxide via electron transfer from NADPH to flavin adenine dinucleotide (FAD) to heme groups to diatomic oxygen. Guanosine triphosphate (GTP), guanosine diphosphate (GDP), homology domain (DH), RAS-related C3 botulinum toxin substrate 2 (Rac2).
From a metabolic perspective, one source of NOX2 activation results when cells experience intermittent hypoxia. Under this condition activation of the metabolic enzyme XO, an enzyme important in the catabolism of purines and a major source of cellular ROS, occurs [24]. XO activation leads to increased ROS, which induces Ca2+ activation of protein kinase C, an enzyme important in cell signalling, migration of p47phox and p67phox to the cell membrane, resulting in activation of the NOX2 complex (Figure 3). Finally it is important to note, from a cell signalling perspective, that extracellular H2O2 (which is rapidly formed from O2\n•−) is readily transported across the cell membrane via the transmembrane water permeable channel protein family of aquaporins [25, 26].
\nROS has been implicated in both HSC quiescence and hematopoietic differentiation. HSC reside in the bone marrow and their quiescence is known to be negatively regulated by ROS. Forkhead box O (FOXO) transcription factors are involved in cell-cycle arrest and apoptosis and are activated in response to oxidative stress whereupon they translocate to the nucleus [27]. Translocation of FOXO4 to the nucleus has been shown to be a function of redox signalling, where oxidation of cys-239 by ROS mediates the formation of disulphide bonds with nuclear import receptor transportin-1, which in turn allows nuclear localization [28]. FOXO deactivation occurs as a result of phosphorylation in response to activation of the regulatory cell cycle PI3K/AKT/mTOR pathway, resulting in their export from the nucleus and subsequent degradation in the cytoplasm [29]. Studies in murine HSC have shown that deletion of FOXO3a, which upregulates transcription of Mn-SOD [30], results in decreased HSC renewal [31] which is mediated by the tumor suppressor protein ataxia-telangiectasia mutated (ATM) and is accompanied by elevated ROS levels and myeloid lineage expansion [32]. Deletion of ATM in mice resulted in BM failure which was restored following treatment with antioxidants [33]. In a different study, isolation of murine HSC into ROS high and ROS low populations showed that the ROS low population maintained self-renewal capacity following serial transplantations, whilst the self-renewal capacity of the ROS high population was exhausted following the third serial transplantation. Treatment of the ROS high HSC with the antioxidant N-acetyl cysteine (NAC), the p38 inhibitor SB203508 or rapamycin (a mTOR inhibitor), restored self-renewal activity [34]. Interestingly, the ROS high population in this study also exhibited a decreased ability to adhere to cells containing calcium sensing receptors, whilst NOX generated ROS has additionally been implicated in osteoclast differentiation in human mesenchymal cells, further emphasizing a potential regulatory role of ROS, in the BM niche [35].
\nWhilst these increased ROS levels are associated with HSC losing quiescence, it has also been shown, in the human megakaryocytic cell line MO7e, that hematopoietic cytokines, such as granulocyte macrophage-colony stimulating factor, interleukin-3, stem cell factor and thrombopoietin all increase ROS levels [36]. In megakaryopoiesis, ROS has been shown to increase platelet production and maturation in the chronic myeloid leukemia (CML) cell line MEG-01 and primary human megakaryocytes [37], which in murine models is mediated by the transcription factor NF-E2 [38]. Following lineage commitment, megakaryocyte progenitors undergo endomitosis (chromosomal replication in the absence of cell division), which in murine cells is potentially mediated by NOX1-derived ROS [39]. In human HSC, NOX-derived ROS has also been shown to be crucial for megakaryocyte differentiation via activation of ERK, AKT and JAK2 signalling pathways [40], whilst another study revealed the importance of cytochrome P450 2E1-generated ROS in megakaryocyte differentiation in human HSC [41]. As noted above, increased ROS in HSC has been associated with expanded myelopoiesis. Interestingly, a recent study using murine CMP, showed that higher levels of ROS impeded megakaryopoiesis, instead directing differentiation of CMP into GMP [42]. Finally, ROS has also been shown to induce differentiation of the promonocytic cell line, U937, into macrophages [43], and the differentiation of primary human monocytes into dendritic cells [44].
\nOne of the first studies implicating ROS in carcinogenesis was performed in mice subcutaneously injected with C3H mouse fibroblasts, that had been previously cultured in vitro with neutrophils stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulated or unstimulated or with the ROS generating enzyme XO and hypoxanthine. In this study approximately 20% of mice treated with these cells developed tumors within 13–22 weeks compared to none of the control mice [45]. In 1991, analysis of H2O2 production in human melanoma, colon, pancreatic, neuroblastoma, breast and ovarian cancer cell lines, revealed constitutively active H2O2 production over a 4 h period, generating H2O2 levels similar to those observed in TPA stimulated neutrophils, suggesting increased ROS production may be a feature of transformation [46]. Later, studies in patients with liver disease suggested ROS plays a part in hepatocarcinogenesis [47], and levels of Cu/Zn-SOD are significantly lower in hepatoma tissue than normal human liver tissue [48]. Further, homozygous deletion of Cu/Zn-SOD in mice results in decreased lifespan, with 70% developing hepatocarcinoma or benign nodular hyperplasia [49], whilst homozygous deletion of Mn-SOD in mice is lethal within two weeks of birth [50]. In the same study, heterozygous deletion of Mn-SOD resulted in increased incidence of hemangioma and adenocarcinoma and significant increases in the incidence of lymphoma. Currently, elevated ROS levels have been reported in many solid tumors and the role they play in tumorigenesis is complex and multifaceted (reviewed in [51]).
\nIn leukemia, a study which collected blood samples from ALL and CML patients samples and compared them with normal blood samples showed elevated levels of ROS in both ALL and CML patients [52], whilst elevated levels of NOX generated ROS, are observed, alongside increased proliferation in both AML models and AML patient samples when compared with healthy controls [53]. Reactions of ROS with DNA can generate numerous oxidised bases, including 8-hydroxy-2-deoxyguanosine (8-OHdG) which causes G:C to T:A DNA transversions (reviewed in [54]). Increased levels of 8-OHdG have been observed in patients with breast cancer [55], gastric carcinomas [56], lung cancer [57] and colorectal cancer [58]. In leukemia, a study of 116 Chinese children with either ALL or AML revealed significantly elevated levels of 8-OHdG, whilst 8-OHdG levels were also significantly elevated in relapsed AML adult patients [59].
\nAs a signalling molecule, ROS can lead to hyperactivation of the PI3K pathway, a common feature of many cancers, resulting in increased cell survival, VEGF production, secretion of MMP (reviewed in [60]) and inactivation of FOXO [32]. In AML, constitutive activation of the PI3K/AKT pathway is frequently observed [61, 62], however the role of FOXO is less clear. A recent study revealed that FOXO1 expression in osteoblasts mediated β-catenin initiated AML [63], whilst a study of AML patient samples showed that 40% exhibited FOXO activation, that upon inhibition resulted in myeloid differentiation and AML cell death [64]. Additionally, in both CML and AML the BCR-ABL fusion protein and FMS-like tyrosine kinase receptor 3 internal tandem duplications (FLT3-ITD) have been shown to lead to phosphorylation of AKT resulting in increased activation of NOX, and increased ROS production (reviewed in [65]), which may in turn reinforce PI3K/AKT activation.
\nBroadly defined, cellular metabolism involves a series of catabolic or anabolic chemical reactions which generate or use energy as part of this process. In chemotrophs this energy is obtained through the oxidation of nutrients, with the energy typically stored in the form of ATP. Whilst in higher organisms a plethora of enzymatically catalyzed metabolic reactions occur, which are all part of different interconnecting metabolic pathways with multitudinous feedback mechanisms. These pathways are evolutionarily highly conserved with the citric acid cycle, for example, essentially a feature in all terrestrial life. There are three main classes of molecules involved in metabolism; carbohydrates, proteins and lipids that are either catabolized to generate energy or energy stores or used by anabolic pathways in the synthesis of, for example, nucleotides and structural molecules such as cell membranes. In mammals, a triumvirate of glycolysis, citric acid cycle and the ETC are central to the generation of ATP, with glycolysis and the citric acid cycle contributing 2 ATP molecules each and the ETC generating up to 34 ATP molecules in a process collectively termed aerobic respiration (reviewed in [66]).
\nGiven the skew towards ATP production in the ETC, Otto Warburg’s observation in 1956 that aerobic glycolysis was a hallmark feature of cancer cells [15], was initially attributed to being the result of defective mitochondria in malignant cells, and initially raised little interest. However, this hypothesis is now known in most cases to be incorrect (reviewed in [67]) and instead, it has been shown that mitochondrial respiration is often necessary in tumorigenesis [68]. However, given its ubiquity and despite its inefficiency when compared with ETC, it is clear that the phenomenon of increased aerobic glycolysis (eponymously titled ‘The Warburg Effect’), must offer cancer cells some competitive advantage, although its exact ontology remains unclear. One hypothesis contends that whilst inefficient, aerobic glycolysis generates ATP at a rate 10–100 times faster than oxidative phosphorylation, therefore supplying cancer cells with energy at a faster rate. This increased glycolytic flux could then, potentially generate more nucleotides, amino acids and lipids for biosynthesis as well as generating the reducing agent NADPH, to deal with the increased levels of ROS common in many cancer cells [69]. Alternatively, increases in excreted lactate as a result of aerobic glycolysis would likely generate a more acidic microenvironment, breaking down stromal membrane structures and potentially increasing cancer cell motility and metastasis [70].
\nIt has been shown that activation of the tumor suppressor protein ATM by ROS promotes glucose-6-phosphate dehydrogenase (G-6-PD) activity, the first step of the pentose phosphate pathway (PPP), which in turn generates NADPH [71]. Given that major cellular antioxidant systems, ultimately rely on NADPH to provide their reducing power, it is perhaps not surprising that ROS in both normal and aberrant cellular processes is inextricably linked with metabolism. In the cytosol, NADPH is primarily generated through the PPP, whilst a number of mechanisms exist for mitochondrial NADPH generation [72], which include the serine synthesis pathway (SSP) (via the folate cycle) [73] and the action of the citric acid cycle enzyme isocitrate dehydrogenase (IDH). IDH1 and IDH2 are commonly mutated in AML [74], although in this context NADPH is consumed, and the D-2-hydroxyglutarate generated leads to stabilization of the hypoxia regulator, hypoxia inducible factor alpha (HIF-1α) [75].
\nHIF-1α as a target of ROS is controversial [76], however it is overexpressed in many cancers where it induces expression of numerous glycolytic genes. The ROS regulated transcription factor nuclear-related factor 2 (NRF2) has also been shown to modulate metabolism in lung cancer cell lines, through the upregulation of enzymes involved in the NADPH production, notably G-6-PD, IDH1 and malic enzyme 1 [77] and high NRF2 levels have previously been reported in AML [78]. Furthermore, the tumor suppressor protein TP53 is also important in regulating metabolism. Homozygous deletion of TP53 in mice results in decreased oxygen consumption arising from decreased mitochondrial respiration [79]. TP53 expression has been shown to inhibit, both glucose transporter (GLUT) 1 and 4 and the glycolytic enzyme phosphoglycerate mutase (PGAM) (reviewed in [80]) leading to decreased glycolysis and potentially increased metabolism via the PPP and SSP. Finally, TP53 also upregulates the apoptosis regulator (TIGAR) an enzyme which has an active domain similar to 6-Phosphofructo-2-kinase/fructoste-2,6-bisphosphatase (PFKFB). TIGAR catalyzes the reaction of fructose-2,6-bisphosphate (F-2,6-BP) to fructose-6-phosphate (F-6-P), which inhibits glycolysis, redirects metabolites into the PPP, generating NADPH [81].
\nChanges of cellular ROS levels in both normal signalling as well cell signalling following cellular transformation result in changes in numerous signalling pathways controlling multiple cellular functions including growth, proliferation and differentiation. A number of these signalling pathways, exercise regulatory control over various metabolic pathways, which in turn modulate ROS levels via several feedback mechanisms (Figure 4). In leukemia, mutations in the RAS gene are present in about 15% of hematological malignancies [82]. RAS activates the PI3K/AKT/mTOR pathway which promotes nucleotide biosynthesis and lipid synthesis (reviewed in [83]) as well as HIF-1α, which upregulate glycolysis via the activation of numerous glycolytic genes. In addition to HIF-1α, other ROS activated transcription factors are important in metabolic regulation such as STAT3, which has been shown to promote glycolysis in hepatocellular carcinoma cell lines [84], FOXO3A, which inhibits glycolysis via activation of tuberous sclerosis 1 protein [85] and NF-κB which was shown to upregulate GLUT3 in mouse embryonic fibroblasts [86].
\nRegulation of metabolic pathways. Schematic illustration outlining some of the regulatory mechanism involved in glycolysis and other key metabolic pathways. Transcription factors are in pink and signalling pathways in blue. Reactive oxygen species (ROS), forkhead box O (FOXO), pyruvate kinase muscle 2 (PKM2), signal transducer and activator of transcription (STAT), nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB), glucose transporter (GLUT) hypoxia inducible factor-1 alpha (HIF-1α), tumour suppressor protein 53 (TP53), glycogen synthase kinase 3β (GSK-3β), isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH), protein kinase B (AKT), mammalian target of rapamycin (mTOR), phosphoinositide 3-kinase (PI3K), synthesis of cytochrome c oxidase 2 (SCO2) and prolyl-hydroxylase domain (PHD).
Nuclear localization of the glycolytic enzyme pyruvate kinase muscle 2 (PKM2) is also ROS mediated, where it acts as a co-factor in the activation of the transcription factor, c-MYC. RAS also activates c-MYC which is overexpressed in greater than 50% of human cancers and c-MYC has been shown to activate glycolysis via the upregulation of GLUT, the glycolytic enzymes hexokinase (HK), phosphoglucose isomerase (PGI), phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), PKM2, as well as lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase 1 (PDK1) and PFKFB3 (reviewed in [87]). Increased glutaminolysis is also a target of c-MYC, which upregulates the glutamine transporter ASCT2 and a key enzyme glutaminase. Additionally, c-MYC was shown to upregulate both phosphoglycerate dehydrogenase (PHGDH) which catalyzes the first step of the SSP, serine hydroxymethyltransferase, part of the folate cycle as well as several genes involved in fatty acid metabolism and the citric acid cycle (reviewed in [67]). In contrast TP53 is known to inhibit glycolysis through inhibition of GLUT1, GLUT4 and PGAM and through activation of TIGAR and synthesis of cytochrome c oxidase 2 (SCO2). Inhibition of glycolysis also occurs due to the regulatory role of miRNA. For example, miR-195-5p inhibits GLUT3, miR-143 inhibits HK2 and miR-155 inhibits HIF-1α. Furthermore, TP53 induces miR-34a which suppresses HK1, HK2, GPI and PDK1, as well as sirtuin 1, which activates FOXO1, NF-κB and in a positive feedback loop TP53 (reviewed in [80]).
\nGiven the role that ROS plays in regulating metabolism, it is not surprising that expression of nearly all enzymes associated with glycolysis have been shown to be altered in solid tumors, a pattern also observed in leukemia. In ALL, micro-array analysis showed significant upregulation of PFK as well as the glucose transporters GLUT1 and GLUT4 in pediatric B-ALL samples [88], whilst deletion of GLUT1 in primary human B-ALL cells suppressed leukemic progression in vivo [89]. In AML, upregulation of GLUT1 mRNA [90] and the fructose transporter GLUT5 [91] have also been reported to be associated with poor outcome in AML patients. Furthermore, NOX generated ROS has previously been reported to modulate cellular glucose uptake through increased GLUT1 activity, in leukemic cell lines [92]. In Philadelphia+ ALL (Ph+ALL) GLUT5 has been found to be upregulated at both the mRNA and protein level [93]. Song et al have identified HK2 overexpression as a feature of AML patients who failed to show remission [90], whilst decreased proliferation in the AML cell line, KG-1, was observed upon knock-down of PGI with shRNA [94]. The HK inhibitors 2-deoxy-D-glucose and 3-bromopyruvate have both been shown to be cytotoxic in AML patient samples harboring a FLT3-ITD mutation both alone and in combination with sorafenib [90, 95]. In chronic lymphocytic leukemia (CLL), a study by Ryland et al., 2013 showed increased expression of glyceraldehyde phosphate dehydrogenase (GAPDH) in CLL patients compared to healthy controls [96]. Proteomic studies revealed elevated levels of aldolase A (ALDO(A)), ALDO(C) and enolase 1 (ENO1) in the chemoresistant leukemia cell line K562/A02 when compared with parental K562 cells and in the case of ENO1 this was confirmed by western blot [97]. Elevated levels of ENO2 have also been reported in patients with ALL where it is associated with lower overall survival [98], whilst PGAM is upregulated in both AML and CML patient samples [99]. LDH is a tetramer which exists as five isoforms, comprising of two subunits LDHA and LDHB in different combinations and encoded by the LDHA and LDHB genes [100], with LDHA strongly catalyzing pyruvate to lactate and LDHB preferentially catalyzing the reverse reaction. In B-ALL, mRNA expression levels of LDHB were shown to be decreased [88], suggesting increased lactate production, whilst more recently increased serum levels of LDH were found in patients with B-ALL in conjunction with increased levels of total oxidant status and decreased total anti-oxidant status [101]. Another recent study involving 204 patients with acute leukemia’s also reported that LDH plasma levels were significantly elevated compared to healthy controls and were also increased in relapse patients compared to those in complete remission [102]. Recently, it was shown that ROS dependent proliferative increases observed in hematopoietic models [103] were also accompanied by increased glucose uptake and expression of the regulatory glycolytic enzyme PFKFB3 [53], whilst downregulation of this enzyme suppressed growth both in vivo and in vitro [16]. This study also reported that metabolomic analysis comparing AML patient samples with high/low levels of ROS, which showed significantly elevated levels of glucose, glucose-6-phosphate (G-6-P) and F-6-P in the ROS high patients. Another metabolomic study involving serum from 400 AML patients compared with 446 healthy controls, identified elevated levels of the glycolytic intermediates 3-phosphoglycerate (3-PG), pyruvate and lactate as conferring a poor prognosis for survival [104]. Interestingly, a recent study showed that the bromodomain and extra-terminal protein inhibitor JQ1, which has shown promise in ALL by targeting c-myc, downregulates expression of HK2, PKM2 and LDHA both at the transcriptional and protein level [105].
\nThe citric acid cycle is a series of metabolic reactions involving oxidation/reduction reactions, which generate nicotinamide adenine dinucleotide (NAD)H and flavin adenine dinucleotide (FAD)H via the transfer of hydride ions, thus providing electrons for the ETC which is a major source of cellular ROS (reviewed in [106]). Mutations of IDH, which catalyzes the decarboxylation of isocitrate to alpha-ketoglutarate are frequently reported in AML (reviewed in [107]). Characterization of the inhibitor AG-221, which has been shown to inhibit mutant IDH2 in AML cells in vitro and in vivo and is currently undergoing phase I/II clinical trials [108], as is the IDH1 inhibitor, AG-120 [109]. A metabolomic study which examined a cohort of 183 patients with de novo AML matched with 232 healthy controls showed significant differences in citrate levels between AML patients and controls [110]. In pediatric ALL a recent metabolomic study revealed increased metabolites of glycolysis, the citric acid cycle and the PPP in patients testing positive for measurable residual disease compared to those testing negative [111]. Interestingly use of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors on ALL cell lines and patient samples showed cytotoxicity in vitro. NAMPT is a key enzyme in the synthesis of the oxidizing agent NAD+, in both glycolysis and the citric acid cycle.
\nThe SSP branches from the glycolytic pathway at the glycolytic intermediate 3-PG, where it is converted into 3-phosphohydroxypyruvate by the enzyme PHGDH, followed by conversion to phosphoserine by phosphoserine aminotransferase 1 and finally to serine by the action of the enzyme phosphoserine phosphatase (reviewed in [73]). Regulation of the SSP is achieved through 2-phosphoglycerate (2-PG) which activates PHGDH whilst serine activates the tetrameric form of PKM2 leading to increased glycolysis and decreased levels of 2-PG. Importantly serine can enter the folate cycle, which provides another route for the generation of NADPH, which has been shown to contribute to tumor growth in vivo [112]. Whilst overexpression of PHGDH has been reported in melanomas, colorectal and breast cancers, little has been published from a leukemia perspective. Knock-down of PHGDH has been shown to inhibit the growth of the leukemia cell line, HL-60 [113], and in multiple myeloma increased expression of PHGDH led to increased SSP activity and antioxidant capacity in cells resistant to treatment with the proteasome inhibitor bortezomib [114].
\nThe PPP generate nucleotides for biosynthesis and is a major source of cellular NADPH, an important cellular antioxidant. The first step involves the dehydrogenation of G-6-P to 6-phosphogluconolactone (6-PG) catalyzed by G-6-PD and the conversion of NADP+ to [115]. Gluconolactonase catalyzes the hydrolysis of 6-PG to 6-phosphogluconate, which is then catalyzed by 6-phosphogluconate dehydrogenase (6-PGD) to ribulose-5-phosphate (Ru-5-P) alongside the generation of a second NADPH. Ru-5-P can then be converted into ribose-5-phosphate (R-5-P) by the enzymatic action of ribulose-5-phosphate isomerase. R-5-P can then be used in the synthesis of nucleotides. Alternatively, where redox homeostasis and not nucleotide synthesis is the major requirement of the cell Ru-5-P can be catalyzed by ribulose-5-phosphate epimerase, into xyulose-5-phosphate (X-5-P) and via a series of further metabolic reactions back into the glycolytic intermediates F-6-P and glyceraldehyde-3-phosphate. G-6-PD is the rate limiting step of the PPP and is regulated by the NADP+/NADPH ratio, RAS/PI3K signalling and phosphorylation by Src, whilst 6-PGD is inhibited by 3-PG [99]. In cancer, aberrant RAS signalling or activation of Src can promote activation of the PPP. In AML, a recent study showed upregulation of G-6-PD mRNA in approximately 60% of patients, although it was not correlated with overall survival or relapse [116]. Targeting of xenograft mice injected with the leukemic cell line K562, with the antimalarial drug dihydroartemisinin and the 6-PGD inhibitor Physicon resulted in decreased tumor growth, whilst primary leukemia cells isolated from the PB of AML patients showed significantly decreased viability, with no toxicity observed in hematopoietic cells isolated from healthy individuals [117]. A metabolomic study comparing primary AML samples with either high or low levels of ROS, have also shown increased levels of the PPP metabolites sedoheptulose-7-phosphate and Ru-5-P in the samples with higher ROS levels [16]. Another study, using both AML cell lines and patient material, showed increased glucose metabolism and increased flux through the PPP, alongside increased G-6-PD mRNA expression [118]. Importantly, this study showed that use of the G-6-PD inhibitor 6-aminonictoinamide (6-AN) in AML cell lines induced both in vitro and in vivo cytotoxicity, and induced apoptosis in primary AML cells but not normal HPCs. In B-ALL, redirection of carbon from the glycolytic pathway to the PPP by the serine/threonine-protein phosphatase 2A (PP2A), has been shown to occur to combat cellular oxidative stress. Synergistic inhibition of G-6-PD by 6-AN and PP2A inhibitor LB100 induced cell death in patient derived Ph+ALL [119].
\nLipid metabolism has also been shown to be dysregulated in both solid tumors and hematological malignancies (reviewed in [120]). Increased fatty acid oxidation (FAO) allows cancer cells to overcome metabolic and oxidative stress through the generation of ATP and NADPH. Significant changes to lipid metabolite levels are seen in AML patient samples with either high levels or low levels of ROS [16], whilst suppression of NOX2 has also been shown to increase FAO [121]. Furthermore, inhibition of the FAO using Avocatin B results in decreased NADPH levels and ROS dependent cell death in primary human AML samples but not normal mononuclear cells [122]. In ALL, use of L-asparaginase has been shown to increase FAO activity as a metabolic escape mechanism, however use of the FAO inhibitor etomoxir in combination with L-asparaginase has been shown to increase sensitivity of both leukemic cell lines and patient samples [123].
\nIn the last twenty years, it has become increasingly clear that ROS play a significant role in cellular signalling, particularly pathways associated with growth, differentiation and survival, whilst its roles in HSC quiescence and normal hematopoiesis have started to be delineated. In many cancers including hematological malignancies, ROS levels have been shown to be elevated, leading to aberrant signalling in these pathways. Previously, arguments for both the use of anti-oxidant and pro-oxidant treatments in leukemia have been made (reviewed in [124]). Despite the transformation of survival rates in patients with acute promyelocytic leukemia using arsenic trioxide [125] cancer cells often upregulate the production of antioxidants, and downregulate pro-apoptotic pathways such as TP53, as a response to high ROS, allowing them to escape apoptosis. In addition, it has been shown that both cancer stem cells [126, 127] and leukemic stem cells [128] exhibit low ROS levels, suggesting that even if treatment with pro-oxidants eliminates the bulk of cancer cells, cancer/leukemic stem cells may survive and relapse occur. Conversely, studies involving the use of antioxidants in treatment and epidemiological studies of antioxidant use, have shown mixed results (reviewed in [129, 130]). Increasingly it is becoming apparent that increased levels of ROS are leading to changes in signalling pathways directly or indirectly controlling metabolism, as a mechanism for managing oxidative stress. Whilst, it has long been known that cancer cells exhibit greatly altered metabolism, only recently have the purposes behind this altered metabolism, started to be elucidated. Consequently, synergistic treatments involving the use of metabolic inhibitors, alongside classical treatments for leukemias are being explored. Future work, elucidating the intricate mechanisms governing the interplay between ROS and metabolism, alongside new and more specific metabolic inhibitors provide much promise for the future treatment of leukemia.
\nWe are grateful to Blood Cancer UK for programmatic funding and to Tenovus Cancer Care for funding Andrew Robinson. We are grateful to Wellcome ISSF for funding aspects of ROS research. We are grateful for support from the NCRI AML trials cell bank and the AML patients for providing primary samples used in several of our studies.
\nThe Internet has irrevocably changed the dynamics of scholarly communication and publishing. Consequently, we find it necessary to indicate, unambiguously, our definition of what we consider to be a published scientific work.
",metaTitle:"Prior Publication Policy",metaDescription:"Prior Publication Policy",metaKeywords:null,canonicalURL:"/page/prior-publication-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"A significant number of working papers, early drafts, and similar work in progress are openly shared online between members of the scientific community. It has become common to announce one’s own research on a personal website or a blog to gather comments and suggestions from other researchers. Such works and online postings are, indeed, published in the sense that they are made publicly available. However, this does not mean that if submitted for publication by IntechOpen they are not original works. We differentiate between reviewed and non-reviewed works when determining whether a work is original and has been published in a scholarly sense or not.
\\n\\nThe significance of Peer Review cannot be overstated when it comes to defining, in our terms, what constitutes a published scientific work. Peer Review is widely considered to be the cornerstone of modern publishing processes and the key value-adding contribution to a scholarly manuscript that a publisher can make.
\\n\\nOther than the issue of originality, research misconduct is another major issue that all publishers have to address. IntechOpen’s Retraction & Correction Policy and various publication ethics guidelines identify both redundant publication and (self)plagiarism to fall within the definition of research misconduct, thus constituting grounds for rejection or the issue of a Retraction if the work has already been published.
\\n\\nIn order to facilitate the tracking of a manuscript’s publishing history and its development from its earliest draft to the manuscript submitted, we encourage Authors to disclose any instances of a manuscript’s prior publication, whether it be through a conference presentation, a newspaper article, a working paper publicly available in a repository or a blog post.
\\n\\nA note to the Academic Editor containing detailed information about a submitted manuscript’s previous public availability is the preferred means of reporting prior publication. This helps us determine if there are any earlier versions of a manuscript that should be disclosed to our readers or if any of those earlier versions should be cited and listed in a manuscript’s references.
\\n\\nSome basic information about the editorial treatment of different varieties of prior publication is laid out below:
\\n\\n1. CONFERENCE PAPERS & PRESENTATIONS
\\n\\nGiven that conference papers and presentations generally pass through some sort of peer or editorial review, we consider them to be published in the accepted scholarly sense, particularly if they are published as a part of conference proceedings.
\\n\\nAll submitted manuscripts originating from a previously published conference paper must contain at least 50% of new original content to be accepted for review and considered for publication.
\\n\\nAuthors are required to report any links their manuscript might have with their earlier conference papers and presentations in a note to the Academic Editor, as well as in the manuscript itself. Additionally, Authors should obtain any necessary permissions from the publisher of their conference paper if copyright transfer occurred during the publishing process. Failure to do so may prevent Us from publishing an otherwise worthy work.
\\n\\n2. NEWSPAPER & MAGAZINE ARTICLES
\\n\\nNewspaper and magazine articles usually do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense. Articles appearing in newspapers and magazines rarely possess the depth and structure characteristic of scholarly articles.
\\n\\nSubmitted manuscripts stemming from a previous newspaper or magazine article will be accepted for review and considered for publication. However, Authors are strongly advised to report any such publication in an accompanying note to the External Editor.
\\n\\nAs with the conference papers and presentations, Authors should obtain any necessary permissions from the newspaper or magazine that published the work, and indicate that they have done so in a note to the External Editor.
\\n\\n3. GREY LITERATURE
\\n\\nWhite papers, working papers, technical reports and all other forms of papers which fall within the scope of the ‘Luxembourg definition’ of grey literature do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense.
\\n\\nAlthough such papers are regularly made publicly available via personal websites and institutional repositories, their general purpose is to gather comments and feedback from Authors’ colleagues in order to further improve a manuscript intended for future publication.
\\n\\nWhen submitting their work, Authors are required to disclose the existence of any publicly available earlier drafts in a note to the Academic Editor. In cases where earlier drafts of the submitted version of the manuscript are publicly available, any overlap between the versions will generally not be considered an instance of self-plagiarism.
\\n\\n4. SOCIAL MEDIA, BLOG & MESSAGE BOARD POSTINGS
\\n\\nWe feel that social media, blogs and message boards are generally used with the same intention as grey literature, to formulate ideas for a manuscript and gather early feedback from like-minded researchers in order to improve a particular piece of work before submitting it for publication. Therefore, we do not consider such internet postings to be publication in the scholarly sense.
\\n\\nNevertheless, Authors are encouraged to disclose the existence of any internet postings in which they outline and describe their research or posted passages of their manuscripts in a note to the Academic Editor. Please note that we will not strictly enforce this request in the same way that we would instructions we consider to be part of our conditions of acceptance for publication. We understand that it may be difficult to keep track of all one’s internet postings in which the researcher´s current work might be mentioned.
\\n\\nIn cases where there is any overlap between the Author´s submitted manuscript and related internet postings, we will generally not consider it to be an instance of self-plagiarism. This also holds true for any co-Author as well.
\\n\\nFor more information on this policy please contact permissions@intechopen.com.
\\n\\nPolicy last updated: 2017-03-20
\\n"}]'},components:[{type:"htmlEditorComponent",content:'A significant number of working papers, early drafts, and similar work in progress are openly shared online between members of the scientific community. It has become common to announce one’s own research on a personal website or a blog to gather comments and suggestions from other researchers. Such works and online postings are, indeed, published in the sense that they are made publicly available. However, this does not mean that if submitted for publication by IntechOpen they are not original works. We differentiate between reviewed and non-reviewed works when determining whether a work is original and has been published in a scholarly sense or not.
\n\nThe significance of Peer Review cannot be overstated when it comes to defining, in our terms, what constitutes a published scientific work. Peer Review is widely considered to be the cornerstone of modern publishing processes and the key value-adding contribution to a scholarly manuscript that a publisher can make.
\n\nOther than the issue of originality, research misconduct is another major issue that all publishers have to address. IntechOpen’s Retraction & Correction Policy and various publication ethics guidelines identify both redundant publication and (self)plagiarism to fall within the definition of research misconduct, thus constituting grounds for rejection or the issue of a Retraction if the work has already been published.
\n\nIn order to facilitate the tracking of a manuscript’s publishing history and its development from its earliest draft to the manuscript submitted, we encourage Authors to disclose any instances of a manuscript’s prior publication, whether it be through a conference presentation, a newspaper article, a working paper publicly available in a repository or a blog post.
\n\nA note to the Academic Editor containing detailed information about a submitted manuscript’s previous public availability is the preferred means of reporting prior publication. This helps us determine if there are any earlier versions of a manuscript that should be disclosed to our readers or if any of those earlier versions should be cited and listed in a manuscript’s references.
\n\nSome basic information about the editorial treatment of different varieties of prior publication is laid out below:
\n\n1. CONFERENCE PAPERS & PRESENTATIONS
\n\nGiven that conference papers and presentations generally pass through some sort of peer or editorial review, we consider them to be published in the accepted scholarly sense, particularly if they are published as a part of conference proceedings.
\n\nAll submitted manuscripts originating from a previously published conference paper must contain at least 50% of new original content to be accepted for review and considered for publication.
\n\nAuthors are required to report any links their manuscript might have with their earlier conference papers and presentations in a note to the Academic Editor, as well as in the manuscript itself. Additionally, Authors should obtain any necessary permissions from the publisher of their conference paper if copyright transfer occurred during the publishing process. Failure to do so may prevent Us from publishing an otherwise worthy work.
\n\n2. NEWSPAPER & MAGAZINE ARTICLES
\n\nNewspaper and magazine articles usually do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense. Articles appearing in newspapers and magazines rarely possess the depth and structure characteristic of scholarly articles.
\n\nSubmitted manuscripts stemming from a previous newspaper or magazine article will be accepted for review and considered for publication. However, Authors are strongly advised to report any such publication in an accompanying note to the External Editor.
\n\nAs with the conference papers and presentations, Authors should obtain any necessary permissions from the newspaper or magazine that published the work, and indicate that they have done so in a note to the External Editor.
\n\n3. GREY LITERATURE
\n\nWhite papers, working papers, technical reports and all other forms of papers which fall within the scope of the ‘Luxembourg definition’ of grey literature do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense.
\n\nAlthough such papers are regularly made publicly available via personal websites and institutional repositories, their general purpose is to gather comments and feedback from Authors’ colleagues in order to further improve a manuscript intended for future publication.
\n\nWhen submitting their work, Authors are required to disclose the existence of any publicly available earlier drafts in a note to the Academic Editor. In cases where earlier drafts of the submitted version of the manuscript are publicly available, any overlap between the versions will generally not be considered an instance of self-plagiarism.
\n\n4. SOCIAL MEDIA, BLOG & MESSAGE BOARD POSTINGS
\n\nWe feel that social media, blogs and message boards are generally used with the same intention as grey literature, to formulate ideas for a manuscript and gather early feedback from like-minded researchers in order to improve a particular piece of work before submitting it for publication. Therefore, we do not consider such internet postings to be publication in the scholarly sense.
\n\nNevertheless, Authors are encouraged to disclose the existence of any internet postings in which they outline and describe their research or posted passages of their manuscripts in a note to the Academic Editor. Please note that we will not strictly enforce this request in the same way that we would instructions we consider to be part of our conditions of acceptance for publication. We understand that it may be difficult to keep track of all one’s internet postings in which the researcher´s current work might be mentioned.
\n\nIn cases where there is any overlap between the Author´s submitted manuscript and related internet postings, we will generally not consider it to be an instance of self-plagiarism. This also holds true for any co-Author as well.
\n\nFor more information on this policy please contact permissions@intechopen.com.
\n\nPolicy last updated: 2017-03-20
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5763},{group:"region",caption:"Middle and South America",value:2,count:5227},{group:"region",caption:"Africa",value:3,count:1717},{group:"region",caption:"Asia",value:4,count:10365},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15784}],offset:12,limit:12,total:118187},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0"},books:[{type:"book",id:"8950",title:"Birds - Challenges and Opportunities for Business, Conservation and Research",subtitle:null,isOpenForSubmission:!0,hash:"404a05af45e47e43871f4a0b1bedc6fd",slug:null,bookSignature:"Dr. Heimo Juhani Mikkola",coverURL:"https://cdn.intechopen.com/books/images_new/8950.jpg",editedByType:null,editors:[{id:"144330",title:"Dr.",name:"Heimo",surname:"Mikkola",slug:"heimo-mikkola",fullName:"Heimo Mikkola"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8969",title:"Deserts and Desertification",subtitle:null,isOpenForSubmission:!0,hash:"4df95c7f295de7f6003e635d9a309fe9",slug:null,bookSignature:"Dr. Yajuan Zhu, Dr. Qinghong Luo and Dr. Yuguo Liu",coverURL:"https://cdn.intechopen.com/books/images_new/8969.jpg",editedByType:null,editors:[{id:"180427",title:"Dr.",name:"Yajuan",surname:"Zhu",slug:"yajuan-zhu",fullName:"Yajuan Zhu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8977",title:"Protein Kinase - New Opportunities, Challenges and Future Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"6d200cc031706a565b554fdb1c478901",slug:null,bookSignature:"Dr. Rajesh Kumar Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8977.jpg",editedByType:null,editors:[{id:"329385",title:"Dr.",name:"Rajesh",surname:"Singh",slug:"rajesh-singh",fullName:"Rajesh Singh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9615",title:"Chikungunya",subtitle:null,isOpenForSubmission:!0,hash:"c960d94a63867dd12a8ab15176a3ff06",slug:null,bookSignature:"Dr. Jean Engohang-Ndong",coverURL:"https://cdn.intechopen.com/books/images_new/9615.jpg",editedByType:null,editors:[{id:"180733",title:"Dr.",name:"Jean",surname:"Engohang-Ndong",slug:"jean-engohang-ndong",fullName:"Jean Engohang-Ndong"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9659",title:"Fibroblasts - Advances in Cancer, Autoimmunity and Inflammation",subtitle:null,isOpenForSubmission:!0,hash:"926fa6446f6befbd363fc74971a56de2",slug:null,bookSignature:"Ph.D. Mojca Frank Bertoncelj and Ms. Katja Lakota",coverURL:"https://cdn.intechopen.com/books/images_new/9659.jpg",editedByType:null,editors:[{id:"328755",title:"Ph.D.",name:"Mojca",surname:"Frank Bertoncelj",slug:"mojca-frank-bertoncelj",fullName:"Mojca Frank Bertoncelj"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9662",title:"Vegetation Index and Dynamics",subtitle:null,isOpenForSubmission:!0,hash:"0abf2a59ee63fc1ba4fb64d77c9b1be7",slug:null,bookSignature:"Dr. Eusebio Cano Carmona, Dr. Ricardo Quinto Canas, Dr. Ana Cano Ortiz and Dr. Carmelo Maria Musarella",coverURL:"https://cdn.intechopen.com/books/images_new/9662.jpg",editedByType:null,editors:[{id:"87846",title:"Dr.",name:"Eusebio",surname:"Cano Carmona",slug:"eusebio-cano-carmona",fullName:"Eusebio Cano Carmona"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9667",title:"Neuroimmunology",subtitle:null,isOpenForSubmission:!0,hash:"9cf0e8203ce088c0b84add014fd8d382",slug:null,bookSignature:"Prof. Robert Weissert",coverURL:"https://cdn.intechopen.com/books/images_new/9667.jpg",editedByType:null,editors:[{id:"79343",title:"Prof.",name:"Robert",surname:"Weissert",slug:"robert-weissert",fullName:"Robert Weissert"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9796",title:"Cancers of Childhood and Adolescence - Epidemiology, Diagnosis, Treatment and Prognosis",subtitle:null,isOpenForSubmission:!0,hash:"7c90c97b84629336aa5af2e9797f4cf2",slug:null,bookSignature:"Prof. Dariusz Borys",coverURL:"https://cdn.intechopen.com/books/images_new/9796.jpg",editedByType:null,editors:[{id:"91258",title:"Prof.",name:"Dariusz",surname:"Borys",slug:"dariusz-borys",fullName:"Dariusz Borys"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety - Volume 1",subtitle:null,isOpenForSubmission:!0,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:null,bookSignature:"Dr. Stanislaw P. Stawicki, Michael S. S Firstenberg and Dr. Vikas Yellapu",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",editedByType:null,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9816",title:"Idiopathic Pulmonary Fibrosis",subtitle:null,isOpenForSubmission:!0,hash:"365bb9762ba33db2d07e677690af1772",slug:null,bookSignature:"Dr. Salim Surani and Dr. Venkat Rajasurya",coverURL:"https://cdn.intechopen.com/books/images_new/9816.jpg",editedByType:null,editors:[{id:"15654",title:"Dr.",name:"Salim",surname:"Surani",slug:"salim-surani",fullName:"Salim Surani"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10218",title:"Flagellar Motility in Cells",subtitle:null,isOpenForSubmission:!0,hash:"5fcc15570365a82d9f2c4816f4e0ee2e",slug:null,bookSignature:"Prof. Yusuf Bozkurt",coverURL:"https://cdn.intechopen.com/books/images_new/10218.jpg",editedByType:null,editors:[{id:"90846",title:"Prof.",name:"Yusuf",surname:"Bozkurt",slug:"yusuf-bozkurt",fullName:"Yusuf Bozkurt"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:13},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:3},{group:"topic",caption:"Business, Management and Economics",value:7,count:1},{group:"topic",caption:"Chemistry",value:8,count:6},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:14},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:3},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:27},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:2},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Social Sciences",value:23,count:2},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:99},popularBooks:{featuredBooks:[{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9668",title:"Chemistry and Biochemistry of Winemaking, Wine Stabilization and Aging",subtitle:null,isOpenForSubmission:!1,hash:"c5484276a314628acf21ec1bdc3a86b9",slug:"chemistry-and-biochemistry-of-winemaking-wine-stabilization-and-aging",bookSignature:"Fernanda Cosme, Fernando M. Nunes and Luís Filipe-Ribeiro",coverURL:"https://cdn.intechopen.com/books/images_new/9668.jpg",editors:[{id:"186819",title:"Prof.",name:"Fernanda",middleName:null,surname:"Cosme",slug:"fernanda-cosme",fullName:"Fernanda Cosme"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8620",title:"Mining Techniques",subtitle:"Past, Present and Future",isOpenForSubmission:!1,hash:"b65658f81d14e9e57e49377869d3a575",slug:"mining-techniques-past-present-and-future",bookSignature:"Abhay Soni",coverURL:"https://cdn.intechopen.com/books/images_new/8620.jpg",editors:[{id:"271093",title:"Dr.",name:"Abhay",middleName:null,surname:"Soni",slug:"abhay-soni",fullName:"Abhay Soni"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9660",title:"Inland Waters",subtitle:"Dynamics and Ecology",isOpenForSubmission:!1,hash:"975c26819ceb11a926793bc2adc62bd6",slug:"inland-waters-dynamics-and-ecology",bookSignature:"Adam Devlin, Jiayi Pan and Mohammad Manjur Shah",coverURL:"https://cdn.intechopen.com/books/images_new/9660.jpg",editors:[{id:"280757",title:"Dr.",name:"Adam",middleName:"Thomas",surname:"Devlin",slug:"adam-devlin",fullName:"Adam Devlin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9122",title:"Cosmetic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"207026ca4a4125e17038e770d00ee152",slug:"cosmetic-surgery",bookSignature:"Yueh-Bih Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9122.jpg",editors:[{id:"202122",title:"Prof.",name:"Yueh-Bih",middleName:null,surname:"Tang",slug:"yueh-bih-tang",fullName:"Yueh-Bih Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9043",title:"Parenting",subtitle:"Studies by an Ecocultural and Transactional Perspective",isOpenForSubmission:!1,hash:"6d21066c7438e459e4c6fb13217a5c8c",slug:"parenting-studies-by-an-ecocultural-and-transactional-perspective",bookSignature:"Loredana Benedetto and Massimo Ingrassia",coverURL:"https://cdn.intechopen.com/books/images_new/9043.jpg",editors:[{id:"193200",title:"Prof.",name:"Loredana",middleName:null,surname:"Benedetto",slug:"loredana-benedetto",fullName:"Loredana Benedetto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,isOpenForSubmission:!1,hash:"852e6f862c85fc3adecdbaf822e64e6e",slug:"oxidoreductase",bookSignature:"Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5221},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9668",title:"Chemistry and Biochemistry of Winemaking, Wine Stabilization and Aging",subtitle:null,isOpenForSubmission:!1,hash:"c5484276a314628acf21ec1bdc3a86b9",slug:"chemistry-and-biochemistry-of-winemaking-wine-stabilization-and-aging",bookSignature:"Fernanda Cosme, Fernando M. Nunes and Luís Filipe-Ribeiro",coverURL:"https://cdn.intechopen.com/books/images_new/9668.jpg",editors:[{id:"186819",title:"Prof.",name:"Fernanda",middleName:null,surname:"Cosme",slug:"fernanda-cosme",fullName:"Fernanda Cosme"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8620",title:"Mining Techniques",subtitle:"Past, Present and Future",isOpenForSubmission:!1,hash:"b65658f81d14e9e57e49377869d3a575",slug:"mining-techniques-past-present-and-future",bookSignature:"Abhay Soni",coverURL:"https://cdn.intechopen.com/books/images_new/8620.jpg",editors:[{id:"271093",title:"Dr.",name:"Abhay",middleName:null,surname:"Soni",slug:"abhay-soni",fullName:"Abhay Soni"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9660",title:"Inland Waters",subtitle:"Dynamics and Ecology",isOpenForSubmission:!1,hash:"975c26819ceb11a926793bc2adc62bd6",slug:"inland-waters-dynamics-and-ecology",bookSignature:"Adam Devlin, Jiayi Pan and Mohammad Manjur Shah",coverURL:"https://cdn.intechopen.com/books/images_new/9660.jpg",editors:[{id:"280757",title:"Dr.",name:"Adam",middleName:"Thomas",surname:"Devlin",slug:"adam-devlin",fullName:"Adam Devlin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9122",title:"Cosmetic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"207026ca4a4125e17038e770d00ee152",slug:"cosmetic-surgery",bookSignature:"Yueh-Bih Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9122.jpg",editors:[{id:"202122",title:"Prof.",name:"Yueh-Bih",middleName:null,surname:"Tang",slug:"yueh-bih-tang",fullName:"Yueh-Bih Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8098",title:"Resources of Water",subtitle:null,isOpenForSubmission:!1,hash:"d251652996624d932ef7b8ed62cf7cfc",slug:"resources-of-water",bookSignature:"Prathna Thanjavur Chandrasekaran, Muhammad Salik Javaid, Aftab Sadiq",coverURL:"https://cdn.intechopen.com/books/images_new/8098.jpg",editedByType:"Edited by",editors:[{id:"167917",title:"Dr.",name:"Prathna",middleName:null,surname:"Thanjavur Chandrasekaran",slug:"prathna-thanjavur-chandrasekaran",fullName:"Prathna Thanjavur Chandrasekaran"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editedByType:"Edited by",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editedByType:"Edited by",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editedByType:"Edited by",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8415",title:"Extremophilic Microbes and Metabolites",subtitle:"Diversity, Bioprospecting and Biotechnological Applications",isOpenForSubmission:!1,hash:"93e0321bc93b89ff73730157738f8f97",slug:"extremophilic-microbes-and-metabolites-diversity-bioprospecting-and-biotechnological-applications",bookSignature:"Afef Najjari, Ameur Cherif, Haïtham Sghaier and Hadda Imene Ouzari",coverURL:"https://cdn.intechopen.com/books/images_new/8415.jpg",editedByType:"Edited by",editors:[{id:"196823",title:"Dr.",name:"Afef",middleName:null,surname:"Najjari",slug:"afef-najjari",fullName:"Afef Najjari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,isOpenForSubmission:!1,hash:"852e6f862c85fc3adecdbaf822e64e6e",slug:"oxidoreductase",bookSignature:"Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",editedByType:"Edited by",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"990",title:"Stem Cell Research",slug:"medicine-cell-biology-stem-cell-research",parent:{title:"Cell Biology",slug:"medicine-cell-biology"},numberOfBooks:22,numberOfAuthorsAndEditors:880,numberOfWosCitations:378,numberOfCrossrefCitations:212,numberOfDimensionsCitations:555,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"medicine-cell-biology-stem-cell-research",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8026",title:"Update on Mesenchymal and Induced Pluripotent Stem Cells",subtitle:null,isOpenForSubmission:!1,hash:"48115afa72bcce1bde1e5b0e6c45f1b8",slug:"update-on-mesenchymal-and-induced-pluripotent-stem-cells",bookSignature:"Khalid Ahmed Al-Anazi",coverURL:"https://cdn.intechopen.com/books/images_new/8026.jpg",editedByType:"Edited by",editors:[{id:"37255",title:"Dr.",name:"Khalid Ahmed",middleName:null,surname:"Al-Anazi",slug:"khalid-ahmed-al-anazi",fullName:"Khalid Ahmed Al-Anazi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6913",title:"Innovations in Cell Research and Therapy",subtitle:null,isOpenForSubmission:!1,hash:"5a2a92efd1c7a2ecb4c396b61b6ffb4f",slug:"innovations-in-cell-research-and-therapy",bookSignature:"Zvi Loewy",coverURL:"https://cdn.intechopen.com/books/images_new/6913.jpg",editedByType:"Edited by",editors:[{id:"235950",title:"Ph.D.",name:"Zvi",middleName:null,surname:"Loewy",slug:"zvi-loewy",fullName:"Zvi Loewy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6658",title:"Stromal Cells",subtitle:"Structure, Function, and Therapeutic Implications",isOpenForSubmission:!1,hash:"c215f02d4268e4b7cccdaea141ec8647",slug:"stromal-cells-structure-function-and-therapeutic-implications",bookSignature:"Mani T. Valarmathi",coverURL:"https://cdn.intechopen.com/books/images_new/6658.jpg",editedByType:"Edited by",editors:[{id:"69697",title:"Dr.",name:"Mani T.",middleName:null,surname:"Valarmathi",slug:"mani-t.-valarmathi",fullName:"Mani T. Valarmathi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5369",title:"Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine",subtitle:null,isOpenForSubmission:!1,hash:"711421bf3bdb0e540fc84267b82b1995",slug:"umbilical-cord-blood-banking-for-clinical-application-and-regenerative-medicine",bookSignature:"Ana Colette Mauricio",coverURL:"https://cdn.intechopen.com/books/images_new/5369.jpg",editedByType:"Edited by",editors:[{id:"56285",title:"Prof.",name:"Ana Colette",middleName:null,surname:"Maurício",slug:"ana-colette-mauricio",fullName:"Ana Colette Maurício"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5207",title:"Pluripotent Stem Cells",subtitle:"From the Bench to the Clinic",isOpenForSubmission:!1,hash:"f29f98ebea5d3e1789f5fb5db827f40c",slug:"pluripotent-stem-cells-from-the-bench-to-the-clinic",bookSignature:"Minoru Tomizawa",coverURL:"https://cdn.intechopen.com/books/images_new/5207.jpg",editedByType:"Edited by",editors:[{id:"156161",title:"Dr.",name:"Minoru",middleName:null,surname:"Tomizawa",slug:"minoru-tomizawa",fullName:"Minoru Tomizawa"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4609",title:"Progress in Stem Cell Transplantation",subtitle:null,isOpenForSubmission:!1,hash:"abbff25d9b960e013b0623b89cdf7367",slug:"progress-in-stem-cell-transplantation",bookSignature:"Taner Demirer",coverURL:"https://cdn.intechopen.com/books/images_new/4609.jpg",editedByType:"Edited by",editors:[{id:"67350",title:"Prof.",name:"Taner",middleName:null,surname:"Demirer",slug:"taner-demirer",fullName:"Taner Demirer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3861",title:"Adult Stem Cell Niches",subtitle:null,isOpenForSubmission:!1,hash:"fa94a08bfdd9319c91079f1c6926f57a",slug:"adult-stem-cell-niches",bookSignature:"Sabine Wislet-Gendebien",coverURL:"https://cdn.intechopen.com/books/images_new/3861.jpg",editedByType:"Edited by",editors:[{id:"65329",title:"Dr.",name:"Sabine",middleName:null,surname:"Wislet",slug:"sabine-wislet",fullName:"Sabine Wislet"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3827",title:"Pluripotent Stem Cell Biology",subtitle:"Advances in Mechanisms, Methods and Models",isOpenForSubmission:!1,hash:"cefa40b44f921d8f66661757ee394474",slug:"pluripotent-stem-cell-biology-advances-in-mechanisms-methods-and-models",bookSignature:"Craig S. Atwood and Sivan Vadakkadath Meethal",coverURL:"https://cdn.intechopen.com/books/images_new/3827.jpg",editedByType:"Edited by",editors:[{id:"16945",title:"Prof.",name:"Craig",middleName:"S",surname:"Atwood",slug:"craig-atwood",fullName:"Craig Atwood"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3263",title:"Pluripotent Stem Cells",subtitle:null,isOpenForSubmission:!1,hash:"8e3646a06bb8ba1da33cb5ccb0867062",slug:"pluripotent-stem-cells",bookSignature:"Deepa Bhartiya and Nibedita Lenka",coverURL:"https://cdn.intechopen.com/books/images_new/3263.jpg",editedByType:"Edited by",editors:[{id:"139427",title:"Dr.",name:"Deepa",middleName:null,surname:"Bhartiya",slug:"deepa-bhartiya",fullName:"Deepa Bhartiya"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3354",title:"Stem Cell Biology in Normal Life and Diseases",subtitle:null,isOpenForSubmission:!1,hash:"0bbdc22389f4c4ea94547dec65f9b69e",slug:"stem-cell-biology-in-normal-life-and-diseases",bookSignature:"Kamran Alimoghaddam",coverURL:"https://cdn.intechopen.com/books/images_new/3354.jpg",editedByType:"Edited by",editors:[{id:"89450",title:"Prof.",name:"Kamran",middleName:null,surname:"Alimoghaddam",slug:"kamran-alimoghaddam",fullName:"Kamran Alimoghaddam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3427",title:"Neural Stem Cells",subtitle:"New Perspectives",isOpenForSubmission:!1,hash:"43e043afc3a3af46076832b4f784dcca",slug:"neural-stem-cells-new-perspectives",bookSignature:"Luca Bonfanti",coverURL:"https://cdn.intechopen.com/books/images_new/3427.jpg",editedByType:"Edited by",editors:[{id:"154282",title:"Dr.",name:"Luca",middleName:null,surname:"Bonfanti",slug:"luca-bonfanti",fullName:"Luca Bonfanti"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3458",title:"Innovations in Stem Cell Transplantation",subtitle:null,isOpenForSubmission:!1,hash:"09f5e6c6ce440ef556de7c8a02f257e8",slug:"innovations-in-stem-cell-transplantation",bookSignature:"Taner Demirer",coverURL:"https://cdn.intechopen.com/books/images_new/3458.jpg",editedByType:"Edited by",editors:[{id:"84241",title:"Prof.",name:"Taner",middleName:null,surname:"Demirer",slug:"taner-demirer",fullName:"Taner Demirer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:22,mostCitedChapters:[{id:"34558",doi:"10.5772/35847",title:"The Epididymis: Embryology, Structure, Function and Its Role in Fertilization and Infertility",slug:"the-epididymis-embryology-structure-function-and-its-role-in-fertilization-and-infertility",totalDownloads:12817,totalCrossrefCites:8,totalDimensionsCites:16,book:{slug:"embryology-updates-and-highlights-on-classic-topics",title:"Embryology",fullTitle:"Embryology - Updates and Highlights on Classic Topics"},signatures:"Kélen Fabiola Arrotéia, Patrick Vianna Garcia, Mainara Ferreira Barbieri, Marilia Lopes Justino and Luís Antonio Violin Pereira",authors:[{id:"106080",title:"Prof.",name:"Luis",middleName:"Antonio",surname:"Violin Pereira",slug:"luis-violin-pereira",fullName:"Luis Violin Pereira"},{id:"112722",title:"Dr.",name:"Kélen",middleName:null,surname:"Arrotéia",slug:"kelen-arroteia",fullName:"Kélen Arrotéia"},{id:"112724",title:"MSc.",name:"Patrick",middleName:null,surname:"Garcia",slug:"patrick-garcia",fullName:"Patrick Garcia"},{id:"112726",title:"BSc.",name:"Mainara",middleName:null,surname:"Barbieri",slug:"mainara-barbieri",fullName:"Mainara Barbieri"},{id:"112727",title:"BSc.",name:"Marília",middleName:null,surname:"Justino",slug:"marilia-justino",fullName:"Marília Justino"}]},{id:"18220",doi:"10.5772/17574",title:"How do Mesenchymal Stem Cells Repair?",slug:"how-do-mesenchymal-stem-cells-repair-",totalDownloads:4551,totalCrossrefCites:6,totalDimensionsCites:11,book:{slug:"stem-cells-in-clinic-and-research",title:"Stem Cells in Clinic and Research",fullTitle:"Stem Cells in Clinic and Research"},signatures:"Patricia Semedo, Marina Burgos-Silva, Cassiano Donizetti-Oliveira and Niels Olsen Saraiva Camara",authors:[{id:"28751",title:"Prof.",name:"Niels",middleName:"Olsen Saraiva",surname:"Camara",slug:"niels-camara",fullName:"Niels Camara"},{id:"30464",title:"Prof.",name:"Patricia",middleName:null,surname:"Semedo",slug:"patricia-semedo",fullName:"Patricia Semedo"},{id:"30465",title:"BSc.",name:"Cassiano",middleName:null,surname:"Donizetti-Oliveira",slug:"cassiano-donizetti-oliveira",fullName:"Cassiano Donizetti-Oliveira"},{id:"30466",title:"BSc.",name:"Marina",middleName:null,surname:"Burgos-Silva",slug:"marina-burgos-silva",fullName:"Marina Burgos-Silva"}]},{id:"26987",doi:"10.5772/32381",title:"Markers for Hematopoietic Stem Cells: Histories and Recent Achievements",slug:"endothelial-cell-selective-adhesion-molecule-esam-a-novel-hsc-marker",totalDownloads:6711,totalCrossrefCites:7,totalDimensionsCites:11,book:{slug:"advances-in-hematopoietic-stem-cell-research",title:"Advances in Hematopoietic Stem Cell Research",fullTitle:"Advances in Hematopoietic Stem Cell Research"},signatures:"Takafumi Yokota, Kenji Oritani, Stefan Butz, Stephan Ewers, Dietmar Vestweber and Yuzuru Kanakura",authors:[{id:"91282",title:"Dr.",name:"Takafumi",middleName:null,surname:"Yokota",slug:"takafumi-yokota",fullName:"Takafumi Yokota"},{id:"97447",title:"Dr.",name:"Takao",middleName:null,surname:"Sudo",slug:"takao-sudo",fullName:"Takao Sudo"},{id:"97448",title:"Dr.",name:"Kenji",middleName:null,surname:"Oritani",slug:"kenji-oritani",fullName:"Kenji Oritani"},{id:"97450",title:"Prof.",name:"Yuzuru",middleName:null,surname:"Kanakura",slug:"yuzuru-kanakura",fullName:"Yuzuru Kanakura"}]}],mostDownloadedChaptersLast30Days:[{id:"42668",title:"Hematopoietic Stem Cells in Chronic Myeloid Leukemia",slug:"hematopoietic-stem-cells-in-chronic-myeloid-leukemia",totalDownloads:3998,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"stem-cell-biology-in-normal-life-and-diseases",title:"Stem Cell Biology in Normal Life and Diseases",fullTitle:"Stem Cell Biology in Normal Life and Diseases"},signatures:"Antonieta Chávez-González, Sócrates Avilés-Vázquez, Dafne\nMoreno-Lorenzana and Héctor Mayani",authors:[{id:"159656",title:"Dr.",name:"Antonieta",middleName:null,surname:"Chavez-Gonzalez",slug:"antonieta-chavez-gonzalez",fullName:"Antonieta Chavez-Gonzalez"},{id:"160310",title:"Dr",name:"Dafne",middleName:null,surname:"Moreno-Lorenzana",slug:"dafne-moreno-lorenzana",fullName:"Dafne Moreno-Lorenzana"},{id:"160311",title:"Mr.",name:"Socrates",middleName:null,surname:"Aviles-Vazquez",slug:"socrates-aviles-vazquez",fullName:"Socrates Aviles-Vazquez"},{id:"160312",title:"Dr.",name:"Hector",middleName:null,surname:"Mayani",slug:"hector-mayani",fullName:"Hector Mayani"}]},{id:"50390",title:"Human Embryonic Stem Cells and Induced Pluripotent Stem Cells: The Promising Tools for Insulin-Producing Cell Generation",slug:"human-embryonic-stem-cells-and-induced-pluripotent-stem-cells-the-promising-tools-for-insulin-produc",totalDownloads:1278,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"pluripotent-stem-cells-from-the-bench-to-the-clinic",title:"Pluripotent Stem Cells",fullTitle:"Pluripotent Stem Cells - From the Bench to the Clinic"},signatures:"Wilairat Leeanansaksiri, Piyaporn Rattananinsruang and\nChavaboon Dechsukhum",authors:[{id:"181332",title:"Ph.D.",name:"Wilairat",middleName:null,surname:"Leeanansaksiri",slug:"wilairat-leeanansaksiri",fullName:"Wilairat Leeanansaksiri"}]},{id:"18225",title:"Are We There Yet? A Story About Cardiac Stem Cells",slug:"are-we-there-yet-a-story-about-cardiac-stem-cells",totalDownloads:2148,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"stem-cells-in-clinic-and-research",title:"Stem Cells in Clinic and Research",fullTitle:"Stem Cells in Clinic and Research"},signatures:"Shizuka Uchida, Piera De Gaspari and Thomas Braun",authors:[{id:"32665",title:"Prof.",name:"Thomas",middleName:null,surname:"Braun",slug:"thomas-braun",fullName:"Thomas Braun"},{id:"33312",title:"Dr.",name:"Shizuka",middleName:null,surname:"Uchida",slug:"shizuka-uchida",fullName:"Shizuka Uchida"},{id:"33313",title:"Dr.",name:"Piera",middleName:null,surname:"De Gaspari",slug:"piera-de-gaspari",fullName:"Piera De Gaspari"}]},{id:"61292",title:"Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications",slug:"human-placenta-derived-mesenchymal-stromal-cells-a-review-from-basic-research-to-clinical-applicatio",totalDownloads:1100,totalCrossrefCites:3,totalDimensionsCites:6,book:{slug:"stromal-cells-structure-function-and-therapeutic-implications",title:"Stromal Cells",fullTitle:"Stromal Cells - Structure, Function, and Therapeutic Implications"},signatures:"Paz de la Torre, María Jesús Pérez-Lorenzo and Ana I. Flores",authors:null},{id:"51997",title:"Future Perspectives in HLA Typing Technologies",slug:"future-perspectives-in-hla-typing-technologies",totalDownloads:1722,totalCrossrefCites:2,totalDimensionsCites:2,book:{slug:"umbilical-cord-blood-banking-for-clinical-application-and-regenerative-medicine",title:"Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine",fullTitle:"Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine"},signatures:"Andreas Giannopoulos and Anastasios G. Kriebardis",authors:[{id:"187390",title:"Prof.",name:"Anastasios",middleName:null,surname:"Kriebardis",slug:"anastasios-kriebardis",fullName:"Anastasios Kriebardis"},{id:"187488",title:"Dr.",name:"Andreas",middleName:null,surname:"Giannopoulos",slug:"andreas-giannopoulos",fullName:"Andreas Giannopoulos"}]},{id:"53450",title:"Reference Intervals of Platelets, Lymphocytes and Cardiac Biomarkers in Umbilical Cord Blood",slug:"reference-intervals-of-platelets-lymphocytes-and-cardiac-biomarkers-in-umbilical-cord-blood",totalDownloads:1204,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"umbilical-cord-blood-banking-for-clinical-application-and-regenerative-medicine",title:"Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine",fullTitle:"Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine"},signatures:"Hanah Kim, Mina Hur, Hee-Won Moon and Salvatore Di Somma",authors:[{id:"39297",title:"Prof.",name:"Mina",middleName:null,surname:"Hur",slug:"mina-hur",fullName:"Mina Hur"},{id:"40133",title:"Prof.",name:"Hee-Won",middleName:null,surname:"Moon",slug:"hee-won-moon",fullName:"Hee-Won Moon"},{id:"187347",title:"Dr.",name:"Hanah",middleName:null,surname:"Kim",slug:"hanah-kim",fullName:"Hanah Kim"},{id:"187348",title:"Prof.",name:"Salvatore",middleName:null,surname:"Di Somma",slug:"salvatore-di-somma",fullName:"Salvatore Di Somma"}]},{id:"68800",title:"Induced Pluripotent Stem Cells for Clinical Use",slug:"induced-pluripotent-stem-cells-for-clinical-use-1",totalDownloads:819,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"update-on-mesenchymal-and-induced-pluripotent-stem-cells",title:"Update on Mesenchymal and Induced Pluripotent Stem Cells",fullTitle:"Update on Mesenchymal and Induced Pluripotent Stem Cells"},signatures:"Valérie Vanneaux",authors:null},{id:"42648",title:"Recent Advances in Hematopoietic Stem Cell Gene Therapy",slug:"recent-advances-in-hematopoietic-stem-cell-gene-therapy",totalDownloads:3126,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"innovations-in-stem-cell-transplantation",title:"Innovations in Stem Cell Transplantation",fullTitle:"Innovations in Stem Cell Transplantation"},signatures:"Toshihisa Tsuruta",authors:[{id:"64743",title:"Dr.",name:"Toshihisa",middleName:null,surname:"Tsuruta",slug:"toshihisa-tsuruta",fullName:"Toshihisa Tsuruta"}]},{id:"50245",title:"Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells",slug:"modeling-hypertrophic-cardiomyopathy-with-human-induced-pluripotent-stem-cells",totalDownloads:1504,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"pluripotent-stem-cells-from-the-bench-to-the-clinic",title:"Pluripotent Stem Cells",fullTitle:"Pluripotent Stem Cells - From the Bench to the Clinic"},signatures:"Marisa Ojala and Katriina Aalto-Setälä",authors:[{id:"20043",title:"Dr.",name:"Katriina",middleName:null,surname:"Aalto-Setälä",slug:"katriina-aalto-setala",fullName:"Katriina Aalto-Setälä"},{id:"181085",title:"Ph.D.",name:"Marisa",middleName:null,surname:"Ojala",slug:"marisa-ojala",fullName:"Marisa Ojala"}]},{id:"50685",title:"States of Pluripotency: Naïve and Primed Pluripotent Stem Cells",slug:"states-of-pluripotency-na-ve-and-primed-pluripotent-stem-cells",totalDownloads:3037,totalCrossrefCites:4,totalDimensionsCites:7,book:{slug:"pluripotent-stem-cells-from-the-bench-to-the-clinic",title:"Pluripotent Stem Cells",fullTitle:"Pluripotent Stem Cells - From the Bench to the Clinic"},signatures:"Daman Kumari",authors:[{id:"180527",title:"Dr.",name:"Daman",middleName:null,surname:"Kumari",slug:"daman-kumari",fullName:"Daman Kumari"}]}],onlineFirstChaptersFilter:{topicSlug:"medicine-cell-biology-stem-cell-research",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/317147/rafael-de-oliveira-ambrosio",hash:"",query:{},params:{id:"317147",slug:"rafael-de-oliveira-ambrosio"},fullPath:"/profiles/317147/rafael-de-oliveira-ambrosio",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()